The phosphoinoisitide 3-kinase pathway in human cancer: Genetic alterations and therapeutic implications

Current Genomics

Volumn 8, Issue 5, 2007, Pages 271-306

  Arcaro, Alexandre ^a   Guerreiro, Ana S ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Akt signaling; Angiogenesis; FOXO proteins; Metastasis; Phosphorylation

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; CAMPTOTHECIN; CARMUSTINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; G PROTEIN COUPLED RECEPTOR; GEMCITABINE; IC 486068; IMATINIB; KP 372; MAMMALIAN TARGET OF RAPAMYCIN; ONCOPROTEIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; PX 866; RAS PROTEIN; S6 KINASE; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; HUMAN; IN VITRO STUDY; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR VASCULARIZATION;

MAMMALIA;

EID: 38949143728     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920207782446160     Document Type: Review

References (496)

1. Engelman, J. A., Luo, J., Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7: 606-19.
2. Garcia, Z., Kumar, A., Marques, M., Cortes, I., Carrera, A. C. Phosphoinositide 3-kinase controls early and late events in mammalian cell division. EMBO J. 2006, 25: 655-61.
3. Shaw, R. J., Cantley, L. C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441: 424-30.
4. Workman, P., Clarke, P. A., Guillard, S., Raynaud, F. I. Drugging the PI3 kinome. Nat. Biotechnol. 2006, 24: 794-6.
5. Vogt, P. K., Kang, S., Elsliger, M. A., Gymnopoulos, M. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem. Sci. 2007, 32: 342-9.
6. Zhao, J. J., Roberts, T. M. PI3 kinases in cancer: from oncogene artifact to leading cancer target. Sci. STKE 2006, 2006: pe52.
7. Whitman, M., Downes, C. P., Keeler, M., Keller, T., Cantley, L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 1989, 332: 644-6.
8. Whitman, M., Kaplan, D., Roberts, T., Cantley, L. Evidence for two distinct phosphatidylinositol kinases in fibroblasts. Implications for cellular regulation. Biochem. J. 1987, 247: 165-74.
9. Kaplan, D. R., Whitman, M., Schaffhausen, B., Pallas, D. C., White, M., Cantley, L., Roberts, T. M. Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity. Cell 1987, 50: 1021-9.
10. Talmage, D. A., Freund, R., Young, A. T., Dahl, J., Dawe, C. J., Benjamin, T. L. Phosphorylation of middle T by pp60c-src: a switch for binding of phosphatidylinositol 3-kinase and optimal tumorigenesis. Cell 1989, 59: 55-65.
11. Fukui, Y., Saltiel, A. R., Hanafusa, H. Phosphatidylinositol-3 kinase is activated in v-src, v-yes, and v-fps transformed chicken embryo fibroblasts. Oncogene 1991, 6: 407-11.
12. Varticovski, L., Daley, G. Q., Jackson, P., Baltimore, D., Cantley, L. C. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol. Cell Biol. 1991, 11: 1107-13.
13. Carpenter, C. L., Duckworth, B. C., Auger, K. R., Cohen, B., 0Schaffhausen, B. S., Cantley, L. C. Purification and characterization of phosphoinositide 3-kinase from rat liver. J. Biol. Chem. 1990, 265: 19704-11.
14. Otsu, M., Hiles, I, Gout, I., Fry, M. J., Ruiz-Larrea, F., Panayotou, G., Thompson, A., Dhand, R., Hsuan, J., Totty, N., et al. Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell 1991, 65: 91-104.
15. Hiles, I. D., Otsu, M., Volinia, S., Fry, M. J., Gout, I., Dhand, R., Panayotou, G., Ruiz-Larrea, F., Thompson, A., Totty, N. F., et al. Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell, 1992, 70: 419-29.
16. Escobedo, J. A., Navankasattusas, S., Kavanaugh, W. M., Milfay, D., Fried, V. A., Williams, L. T. cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF beta-receptor. Cell 1991, 65: 75-82.
17. Skolnik, E. Y., Margolis, B., Mohammadi, M., Lowenstein, E., Fischer, R., Drepps, A., Ullrich, A., Schlessinger, J. Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell 1991, 65: 83-90.
18. Fantl, W. J., Escobedo, J. A., Martin, G. A., Turck, C. W., del Rosario, M., McCormick, F., Williams, L. T. Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways. Cell 1992, 69: 413-23.
19. McGlade, C. J., Ellis, C., Reedijk, M., Anderson, D., Mbamalu, G., Reith, A. D., Panayotou, G., End, P., Bernstein, A., Kazlauskas, A., et al. SH2 domains of the p85 alpha subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors. Mol. Cell Biol. 1992, 12: 991-7.
20. Klippel, A., Escobedo, J. A., Fantl, W. J., Williams, L. T. The C-terminal SH2 domain of p85 accounts for the high affinity and specificity of the binding of phosphatidylinositol 3-kinase to phosphorylated platelet-derived growth factor beta receptor. Mol. Cell Biol. 1992, 12: 1451-9.
21. Reedijk, M., Liu, X., van der Geer, P., Letwin, K., Waterfield, M. D., Hunter, T., Pawson, T. Tyr721 regulates specific binding of the CSF-1 receptor kinase insert to PI3'-kinase SH2 domains: a model for SH2-mediated receptor-target interactions. EMBO J. 1992, 11: 1365-72.
22. Panayotou, G., Bax, B., Gout, I., Federwisch, M., Wroblowski, B., Dhand, R., Fry, M. J., Blundell, T. L., Wollmer, A., Waterfield, M. D. Interaction of the p85 subunit of PI3-kinase and its N-terminal SH2 domain with a PDGF receptor phosphorylation site: structural features and analysis of conformational changes. EMBO J. 1992, 11: 4261-72.
23. Graziani, A., Gramaglia, D., Cantley, L. C., Comoglio, P. M. The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J. Biol. Chem. 1991, 266: 22087-90.
24. Bardelli, A., Maina, F., Gout, I., Fry, M. J., Waterfield, M. D., Comoglio, P. M., Ponzetto, C. Autophosphorylation promotes complex formation of recombinant hepatocyte growth factor receptor with cytoplasmic effectors containing SH2 domains. Oncogene 1992, 7: 1973-8.
25. Ponzetto, C., Bardelli, A., Zhen, Z., Maina, F., dalla Zonca, P., Giordano, S., Graziani, A., Panayotou, G., Comoglio, P. M. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994, 77: 261-71.
26. Rottapel, R., Reedijk, M., Williams, D. E., Lyman, S. D., Anderson, D. M., Pawson, T., Bernstein, A. The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor. Mol. Cell Biol. 1991, 11: 3043-51.
27. Lev, S., Givol, D., Yarden, Y. A specific combination of substrates is involved in signal transduction by the kit-encoded receptor. EMBO J. 1991, 10: 647-54.
28. Yamamoto, K., Lapetina, E. G., Moxham, C. P. Insulin like growth factor-I induces limited association of phosphatidylinositol 3-kinase to its receptor. Endocrinology 1992, 130: 1490-8
29. Yamamoto, K., Altschuler, D., Wood, E., Horlick, K., Jacobs, S., Lapetina, E. G. Association of phosphorylated insulin-like growth factor-I receptor with the SH2 domains of phosphatidylinositol 3-kinase p85. J. Biol. Chem. 1992, 267: 11337-43.
30. Giorgetti, S., Ballotti, R., Kowalski-Chauvel, A., Tartare, S., Van Obberghen, E. The insulin and insulin-like growth factor-I receptor substrate IRS-I associates with and activates phosphatidylinositol 3-kinase in vitro. J. Biol. Chem. 1993, 268: 7358-64.
31. Sun, X. J., Rothenberg, P., Kahn, C. R., Backer, J. M., Araki, E., 'Wilden, P. A., Cahill, D. A., Goldstein, B. J.. White, M. F. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991, 352: 73-7.
32. Lavan, B. E., Kuhne, M. R., Gamer. C. W., Anderson, D., Reedijk, M., Pawson, T., Lienhard, G. E. The association of insulin-elicited phosphotyrosine proteins with src homology 2 domains. J. Biol. Chem. 1992, 267: 11631-6.
33. Backer, J. M., Myers, M. G., Jr., Shoelson, S. E., Chin, D. J., Sun, X. J., Miralpeix, M., Hu, P., Margolis, B., Skolnik, E. Y., Schlessinger, J., et al. Phosphatidylinositol 3′-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J. 1992, 11: 3469-79.
34. Myers, M. G., Jr., Backer, J. M., Sun, X. J., Shoelson, S., Hu, P., Schlessinger, J., Yoakim, M., Schaffhausen, B., White, M. F. IRS-1 activates phosphatidylinositol 3′-kinase by associating with src homology 2 domains of p85. Proc. Natl. Acad. Sci. USA 1992, 89: 10350-4.
35. Peles, E., Lamprecht, R., Ben-Levy, R., Tzahar, E., Yarden, Y. Regulated coupling of the Neu receptor to phosphatidylinositol 3′-kinase and its release by oneogenic activation. J. Biol. Chem. 1992, 267: 12266-74.
36. Fedii, P., Pierce, J. H., di Fiore, P. P., Kraus, M. H. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol. 1994, 14: 492-500.
37. Soltoff, S. P., Carraway, K. L., 3rd, Prigent, S. A., Gullick, W. G., Cantley, L. C. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol. 1994, 14: 3550-8.
38. Prigent, S. A., Gullick, W. J. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/ c-erbB-3 chimera. EMBO J. 1994, 13: 2831-41.
39. Escobedo, J. A., Kaplan, D. R., Kavanaugh, W. M., Turck, C. W., Williams, L. T. A phosphatidylinositol-3 kinase binds to platelet-derived growth factor receptors through a specific receptor sequence containing phosphotyrosine. Mol Cell Biol. 1991, 11: 1125-32.
40. Kazlauskas, A., Cooper, J. A. Phosphorylation of the PDGF receptor beta subunit creates a tight binding site for phosphatidylinositol 3 kinase. EMBO J. 1990, 9: 3279-86.
41. Soltoff, S. P., Rabin, S. L., Cantley, L. C., Kaplan, D. R. Nerve growth factor promotes the activation of phosphatidylinositol 3-kinase and its association with the trk tyrosine kinase. J Biol. Chem. 1992, 267: 17472-7.
42. Ohmichi, M., Decker, S. J., Saltiel, A. R. Activation of phosphatidylinositol-3 kinase-by nerve growth factor involves indirect coupling of the trk proto-oncogene with src homology 2 domains. Neuron 1992, 9: 769-77.
43. Obermeier, A., Lammers, R., Wiesmuller, K. H., Jung, G., Schlessinger, J., Ullrich, A. Identification of Trk binding sites for SHC and phosphatidylinositol 3′-kinase and formation of a multimeric signaling complex. J. Biol. Chem. 1993, 268: 22963-6.
44. 3 receptor tyrosine kinase. Oncogene 1994 9: 175-65.
45. Kanakura, Y., Furitsu, T., Tsujimura, T., Butterfield, J. H., Ashman, L. K., Ikeda, H., Kitayama, H., Kanayama, Y., Matsuzawa, Y., Kitamura, Y. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia 1994, 8 Suppl I: S18-22.
46. Fixman, E. D., Naujokas, M. A., Rodrigues, G. A., Moran, M. F., Park, M. Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus. Oncogene 1995, 10: 237-49.
47. Moscàtello, D. K., Holgado-Madruga, M., Emlet, D. R., Montgomery, R. B., Wong, A. J. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem. 1998, 273: 200-6.
48. Gotoh, A., Miyazawa, K., Ohyashiki, K., Toyama, K. Potential molecules implicated in downstream signaling pathways of pl85BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3'-kinase. Leukemia 1994, 8: 115-20.
49. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., Downward, J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370: 527-32.
50. Kodaki, T., Woscholski, R., Hallberg, B., Rodriguez-Viciana, P., Downward, J., Parker, P. J. The activation of phosphatidylinositol 3-kinase by Ras. Curr. Biol. 1994, 4: 798-806.
51. Campbell, P. M., Der, C. J. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol. 2004, 14: 105-14.
52. Klinghoffer, R. A., Duckworth, B., Valius, M., Cantley, L., Kazlauskas, A. Platelet-derived growth factor-dependent activation of pbosphatidylinositol 3-kinase is regulated-by receptor binding of SH2-domain-containing proteins which influence Ras activity. Mol. Cell Biol. 1996, 16: 5905-14.
53. Chan, T. O., Rodeck, U., Chan, A. M., Kimmelman, A. C., Rittenhouse, S. E., Panayotou, G., Tsichlis, P. N. Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell 2002, 1: 181-91.
54. Gonzalez-Garcia, A., Garrido, E., Hernandez, C., Alvarez, B., Jimenez, C., Cantrell, D. A., Pullen, N., Carrera, A. C. A new role for the p85-phosphatidylinositol 3-kinase regulatory subunit linking FRAP to p70 S6 kinase activation. J. Biol. Chem. 2002, 277: 1500-8.
55. Auger, K. R., Serunian, L. A., Soltoff, S. P., Libby, P., Cantley, L. C. PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell 1989, 57: 167-75.
56. Hawkins, P. T., Jackson, T. R., Stephens, L. R. Platelet-derived growth factor stimulates synthesis of PtdIns(3,4,5)P3 by activating a PtdIns(4,5)P2 3-OH kinase. Nature 1992, 358: 157-9.
57. Serunian, L. A., Haber, M. T., Fukui, T., Kim, J. W., Rhee, S. G., Lowenstein, J. M., Cantley, L. C. Polyphosphoinositides produced by phosphatidylinositol 3-kinase are poor substrates for phospholipases C from rat liver and bovine brain. J. Biol. Chem. 989, 264: 17809-15.
58. Vanhaesebroeck, B., Leevers, S. J., Panayotou, G., Waterfield, M. D. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem. Sci. 1997, 22: 267-72.
59. Vanhaesebroeck, B., Waterfield, M. D. Signaling by distinct classes of pbosphoinositide 3-kinases. Exp. Cell Res. 1999, 253: 239-54.
60. Foster, F. M., Traer, C. J., Abraham, S. M., Fry, M. J. The phosphoinositide (PI) 3-kinase family. J. Cell Sci. 2003, 116: 3037-40.
61. Pons, S., Asano, T., Glasheen, E., Miralpeix, M., Zhang, Y., Fisher, T.L., Myers, M. G., Jr., Sun, X. J., White, M. F. The structure and function of p55PIK reveal a new regulatory subunit for phosphatidylinositol 3-kinase. Mol. Cell Biol. 1995, 15: 4453-65.
62. Inukai, K., Anai, M., Van Breda, E., Hosaka, T., Katagiri, H., Funaki, M., Fukushima, Y., Ogihara, T., Yazaki, Y., Kikuchi, Oka, Y., Asano, T. A novel 55-kDa regulatory subunit for phosphatidylinositol 3-kinase structurally similar to p55PIK Is generated by alternative splicing of the p85alpha gene. J. Biol. Chem. 1996, 271: 5317-20.
63. Inukai, K., Funaki, M., Ogihara, T., Katagiri, H., Kanda, A., Anai, M., Fukushima, Y., Hosaka, T., Suzuki, M., Shin, B. C., Takata, K., Yazaki, Y., Kikuchi, M., Oka, Y., Asano, T. p85alpha gene generates three isoforms of regulatory subunit for phosphatidylinositol 3-kinase (PI 3-Kinase), p50alpha, p55alpha, and p85alpha, with different PI 3-kinase activity elevating responses to insulin. J. Biol. Chem. 1997, 272: 7873-82.
64. Dey, B. R., Furlanetto, R. W., Nissley, S. P. Cloning of human p55 gamma, a regulatory subunit of phosphatidylinositol 3-kinase, by a yeast two-hybrid library screen with the insulin-like growth factor-I receptbr. Gene 1998, 209: 175-83.
65. Hu, P., Mondino, A., Skolnik, E. Y., Schlessinger, J. Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. Mol. Cell Biol. 1993, 13: 7677-88.
66. Chantry, D., Vojtek, A., Kashishian, A., Holtzman, D. A., Wood, C, Gray, P. W., Cooper, J. A., Hoekstra, M. F. pl10delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J. Mol. Chem. 1997, 272: 19236-41.
67. Vanhaesebroeck, B., Welham, M. J., Kotani, K., Stein, R., Warne, P. H., Zvelebil, M.. J., Higashi, K., Volinia, S., Downward, J., Waterfield, M. D. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc. Natl. Acad. Sci. USA 1997, 94: 4330-5.
68. Stephens, L., Eguinoa, A., Corey, S., Jackson, T., Hawkins, P. T. Receptor stimulated accumulation of phosphatidylinositol (3,4,5)- trisphosphate by G-protein mediated pathways in human myeloid derived cells. EMBO J. 1993, 12: 2265-73.
69. Stephens, L., Jackson, Hawkins, P. T. Synthesis of phosphatidylinositol 3,4,5-trisphosphate in permeabilized neutrophils regulated by receptors and G-proteins. J. Biol. Chem. 1993, 268: 17162-72.
70. Stephens, L., Smrcka, A., Cooke, F. T., Jackson, T. R., Sternweis, P. C., Hawkins, P. T. A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits. Cell 1994, 77: 83-93.
71. Stoyanov, B., Volinia, S., Hanck, T., Rubio, I., Loubtchenkov, M., Malek, D., Stoyanova, S., Vanhaesebroeck, B., Dhand, R., Nurnberg, B., et al. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 1995, 269: 690-3.
72. Stephens, L. R., Eguinoa, A., Erdjument-Bromage, H., Lui, M., Cooke, F., Coadwell, J., Smrcka, A. S., Thelen, M., Cadwallader, K., Tempst, P., Hawkins, P. T. The G beta gamma sensitivity of a P13K is dependent upon a tightly associated adaptor, pl0l. Cell 1997, 89: 105-14.
73. Kurosu, H., Maehama, T., Okada, T., Yamamoto, T., Hoshino, S,, Fukui, Y., Ui, M., Hazeki, O., Katada, T. Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110beta is synergistically activated by the betagamma subunits of G proteins and phosphotyrosyl peptide. J. Biol. Chem. 1997, 272: 24252-6.
74. Suire, S., Hawkins, P., Stephens, L. Activation of phosphoinositide 3-kinase gamma by Ras. Curr. Biol. 2002, 12: 1068-75.
75. Pacold, M. E., Suire, S., Perisic, O., Lam-Gonzalez, S., Davis, C. T., Walker, E. H., Hawkins, P. T., Stephens, L., Eccleston, J. F., Williams, R. L. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 2000, 103: 931-43.
76. Molz, L., Chen, Y. W., Hirano, M., Williams, L. T. Cpk is a novel class of Drosophila. Ptdlns 3-kinase containing a C2 domain. J. Biol. Chem. 1996, 271: 13892-9.
77. Virbasius, J. V., Guilherme, A., Czech, M. P. Mouse p170 is a novel phosphatidylinositol 3-kinase containing a C2 domain. J. Biol. Chem. 1996, 271: 13304-7.
78. MacDougall, L. K., Domin, J., Waterfield, M. D. A family of phosphoinositide 3-kinases in Drosophila identifies a new mediator of signal transduction. Curr. Biol. 1995, 5: 1404-15.
79. Brown, R. A., Ho, L. K., Weber, Hall, S. J., Shipley, J. M., Fry, M., J. IdentificAtion and cDNA cloning ofs novel mammalian C2 domain-containing phosphoinositide 3-kinase, HsC2-P13K. Biochem. Biophys. Res. Commun. 1997, 233: 537-44.
80. Ho, L. K., Liu, D., Rozycka, M., Brown, R. A., Fry, M. J. Identification of four novel human phosphoinositide 3-kinases defines a multi-isoform subfamily. Biochem. Biophys. Res. Commun., 1997 235: 130-7.
81. Domin, J., Pages, F., Volinia, S., Rittenhouse, S. E., Zvelebil, M. J., Stein, R. C., Waterfield, M. D. Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem. J. 1997, 326 (Pt I): 139-47.
82. Misawa, H., Ohtsubo, M., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Yoshimura, A. Cloning and characterization of a novel class II phosphoinositide 3-kinase containing C2 domain. Biochem. Biophys. Res. Commun. 1998, 244: 531-9.
83. Arcaro, A., Volinia, S., Zvelebil, M. J., Stein, R., Watton, S. J., Layton, M. J., Gout, I., Ahmadi, K., Downward, J., Waterfield, M. D. Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity. J. Biol. Chem. 1998, 273: 33082-90.
84. Ono, F., Nakagawa, T., Saito, S., Owada, Y., Sakagami, H., Goto, K., Suzuki, M., Matsuno, S., Kondo, H. A novel class II phosphoinositide 3-kinase predominantly expressed in the liver and its enhanced expression during liver regeneration. J. Biol. Chem. 1999, 273: 7731-6.
85. Scbu, P. V., Takegawa, K., Fry, M. J., Stack, J. H., Waterfield, M. D., Emr, S. D. Phosphatidylinositol 3-kinase encoded by yeast VPS34 gene essential for protein sorting. Science 1993, 260: 88-91.
86. Stack, J. H., Herman, P. K., Schu, P. V., Emr, S. D. A membrane-associated complex containing the VpsI5 protein kinase and the Vps34 PI 3-kinase is essential for protein sorting to the yeast lysosome-like vacuole. EMBO J. 1993, 12: 2195-204.
87. Volinia, S., Dhand, R., Vanhaesebroeck, B., MacDougall, L. K., Stein, R., Zvelebil, M. J., Domin, J., Panaretou, C., Waterfield, M. D. A human phosphatidylinositol 3-kinase complex related to the yeast Vps34p-Vps15p protein sorting system. EMBO J. 1995, 14: 3339-48.
88. Panaretou, C., Domin, J., Cockcroft, S., Waterfield, M. D. Characterization of p150, an adaptor protein for the human phosphatidylinositol (PtdIns) 3-kinase. Substrate presentation by phosphatidylinositol transfer protein to the p150.Ptdins 3-kinase complex. J. Biol. Chem. 1997, 272: 2477-85.
89. Linassier, C., MacDougall, L. K., Domin, J., Waterfield, M. D. Molecular cloning and biochemical characterization of a Drosophila phosphatidylinositol-specific phosphoinositide 3-kinase. Biochem. J. 1997, 321 (Pt 3): 849-56.
90. Hickinson, D. M., Lucocq, J. M., Towler, M. C., Clough, S., James, J., James, S. R., Downes, C. P., Ponnambalam, S. Association of a phosphatidylinositol-specific 3-kinase with a human trans-Golgi network resident protein. Curr. Biol. 1997, 7: 987-90.
91. Kunz, J., Henriquez, R., Schneider, U., Deuter-Reinhard, M., Movva, N. R., Hall, M. N. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 1993, 73: 585-96.
92. Helliwell, S. B., Wagner, P., Kunz, J., Deuter-Reinhard, M., Henriquez, R., Hall, M. N. TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. Mol. Biol. Cell 1994, 5: 105-18.
93. Brown, E. J., Albers, M. W., Shin, T. B., Ichikawa, K., Keith, C. T., Lane, W. S., Schreiber, S. L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369: 756-8.
94. Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., Snyder, S. H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994, 78: 35-43.
95. Chiu, M. I., Katz, H., Berlin, V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc. Natl. Acad. Sci. USA 1994, 91: 12574-8.
96. Schmelzle, T., Hall, M. N. TOR, a central controller of cell growth. Cell 2000, 103: 253-62.
97. Savitsky, K., Bai-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle, D. A., Smith, S., Uziel, T., Sfez, S., Ashkenazi, M., Pecker, I., Frydman, M., Harnik, R., Patanjali, S. R., Simmons, A., Clines, G. A.; Sartiel, A., Gatti, R. A., Chessa, L., Sanal, O., Lavin, M. F., Jaspers, N. G., Taylor, A. M., Arlett, C. F., Miki, T., Weissman, S. M., Lovett, M., Collins, F. S., Shiloh, Y. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995, 268: 1749-53.
98. Zhang, N., Chen, P, Khanna, K. K., Scott, S., Gatei, M., Kozlov, S., Watters, D., Spring, K., Yen, T., Lavin, M. F. Isolation of full-length ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype. Proc. Natl. Acad. Sci. USA 1997, 94: 8021-6.
99. Hartley, K. O., Gell, D., Smith, G. C., Zhang, H., Divecha, N., Connelly, M. A., Admon, A., Lees-Miller, S. P., Anderson, C. W., Jackson, S. P. DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product. Cell 1995, 82: 849-56.
100. Booker, G. W., Gout, I., Downing, A. K., Driscoll, P. C., Boyd, J., Waterfield, M. D., Campbell, I. D. Solution structure and ligand-binding site of the SH3 domain of the p85 alpha subunit of phosphatidylinositol 3-kinase. Cell 1993, 73: 813-22.
101. Booker, G. W., Breeze, A. L., Downing, A. K., Panayotou, O., Gout, I., WaterfieK M. D., Campbell, I. D. Structure of an SH2-domain of the p85 alpha subunit of phosphatidylinositol-3-OH kinase. Nature 1992, 358: 684-7.
102. Klippel, A., Escobedo, J. A., Hu, Q., Williams, L. T. A region of the 85-kilodalton (kDa) subunit of phosphatidylinositol 3-kinase binds the 110-kDa catalytic subunit in vivo. Mol. Cell Biol. 1993, 13: 5560-6.
103. Holt, K. H., Olson, L., Moye-Rowley, W. S., Pessin, J. E. Phosphatidylinositol 3-kinase activation is mediated by high-affinity interactions between distinct domains within the p110 and p85 subunits. Mol. Cell Biol. 1994, 14: 42-9.
104. Dhand, R., Hara, K., Hiles, I., Bax, B., Gout, I., Panayotou, G., Fry, M. J., Yonezawa, K., Kasuga, M, Waterfield, M. D. PI 3-kinase: structural and functional analysis of intersubunit interactions. EMBO J. 1994, 13: 511-21.
105. Hu, P., Schlessinger, J. Direct association of p110 beta phosphatidylinositol 3-kinase with p85 is mediated by an N-terminal fragment of p110 beta. Mol. Cell Biol. 1994, 14: 2577-83.
106. Kapeller, R., Prasad, K. V., Janssen, O., Hou, W., Schaffhausen, B. S., Rudd, C. E., Cantley, L. C. Identification of two SH3-binding motifs in the regulatory subunit of phosphatidylinositol 3-kinase. J. Biol. Chem 1994, 269: 1927-33.
107. Pleiman, C. M., Hertz, W. M., Cambier, J. C. Activation of phosphatidylinositol-3' kinase by Src-family kinase SH3 binding to the p85 subunit. Science 1994, 263: 1609-12.
108. Musacchio, A., Cantley, L. C., Harrison, S. C. Crystal structure of the breakpoint cluster region-homology domain fforn phosphoinositide 3-kinase p85 alpha subunit. Proc. Natl. Acad. Sci. USA 1996, 93: 14373-8.
109. Walker, E. H., Perisic, O., Ried, C., Stephens, L., Williams, R. L. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 1999, 402: 313-20.
110. Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., Williams, R. L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 2000, 6: 909-9.
111. Valius, M., Kazlauskas, A. Phospholipase C-gamma 1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal. Cell 1993, 73: 321-34.
112. van der Geer, P., Hunter, T. Mutation of Tyr697, a GRB2-binding site, and Tyr721, a PI 3-kinase binding site, abrogates signal transduction by the murine CSF-1 receptor expressed m Rat-2 fibroblasts. EMBO J. 1993, 12: 5161-72.
113. Joly, M., Kazlauskas, A., Fay, F. S., Corvera, S. Disruption of PDGF receptor trafficking by mutation of its PI-3 kinase binding sites. Science 1994, 263: 684-7.
114. Wennstrom, S., Hawkins, P., Cooke, F., Hara, K., Yonezawa, K., Kasuga, M., Jackson, T., Claesson-Welsh, L., Stephens, L. Activation of phosphoinositide 3-kinase is required for PDGF-stimulated membrane ruffling. Curr. Biol. 1994, 4: 385-94.
115. Kundra, V., Escobedo, J. A., Kazlauskas, A., Kim, H. K., Rhee, S. G., Williams, L. T., Zetter, B. R. Regulation of chemotaxis by the platelet-derived growth factor receptor-beta. Nature 1994, 367: 474-6.
116. Vlahos, C. J., Matter, W. F., Hui, K. Y., Brown, R. F. A specific inhibitor of phosphatidylinositol 3-Kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 1994, 269: 5241-8.
117. Arcaro, A., Wymann, M. P. Wortmannin is a potent phosphatidylinositol 3-Kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem. J. 1993, 296 (Pt 2): 297-301.
118. Yano, H., Nakanishi, S., Kimura, K., Hanai, N., Saitoh, Y., Fukui, Y., Nonomura, Y., Matsuda, Y. Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J. Biol. Chem. 1993, 268: 25846-56.
119. Powis, G., Bonjouklian, R., Berggren, M. M., Gallegos, A., Abraham, R., Ashendel, C., Zalkow, L, Matter, W. F., Dodge, J., Grindey, G., et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res. 1994, 54: 2419-23.
120. Brunn, G. J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, J. C., Jr., Abraham, R. T. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 1996, 15: 5256-67.
121. Sarkaria, J. N., Tibbetts, R. S., Busby, E. C., Kennedy, A. P., Hill, D. E., Abraham, R. T. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 1998, 58: 4375-82.
122. Cheatham, B., Vlahos, C. J., Cheatham, L., Wang, L., Blenis, J., Kahn, C. R. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol. Cell Biol. 1994, 14: 4902-11.
123. Chung, J., Grammer, T. C., Lemon, K. P., Kazlauskas, A., Blenis, J. PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 1994, 370: 71-5.
124. Weng, Q. P., Andrabi, K., Kozlowski, M. T., Grove, J. R., Avruch, J. Multiple independent inputs are required for activation of the p70 S6 kinase. Mol. Cell Biol. 1995, 15: 2333-40.
125. Weng, Q. P., Andrabi, K., Klippel, A., Kozlowski, M. T., Williams, L. T., Avruch, J. Phosphatidylinositol 3-kinase signals activation of p70 S6 kinase in situ through site-specific p70 phosphorylation. Proc. Natl. Acad. Sci. USA 1995, 92: 5744-8.
126. Welsh, G. I., Foulstone, E. J., Young, S. W., Tavare, J. M., Proud, C. G. Wortmannin inhibits the effects of insulin and serum on the activities of glycogen synthase kinase-3 and mitogen-activated protein kinase. Biochem J. 1994, 303 (Pt 1): 15-20.
127. Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., Tsichlis, P. N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995, 81: 727-36.
128. Burgering, B. M., Coffer, P. J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995, 376: 599-602.
129. Kohn, A. D., Kovacina, K. S., Roth, R. A. Insulin stimulates the kinase activity of RAC-PK, a pleckstrin homology domain containing ser/thr kinase. EMBO J. 1995, 14: 4288-95.
130. Martin, S. S., Haruta, T., Morris, A. J., Klippel, A., Williams, L. T., Olefsky, J. M. Activated phosphatidylinositol 3-kinase is sufficient to mediate actin rearrangement and GLUT4 translocation in 3T3-L1 adipocytes. J. Biol. Chem. 1996, 271: 17605-8.
131. Didichenko, S. A., Tilton, B., Hemmings, B. A., Ballmer-Hofer, K., Thelen, M. Constitutive activation of protein kinase B and phosphorylation of p47phox by a membrane-targeted phosphoinositide 3-kinase. Curr. Biol. 1996, 6: 1271 -8.
132. Klippel, A., Kavanaugh, W. M., Pot, D., Williams, L. T. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol. Cell Biol. 1997, 17: 338-44.
133. Franke, T. F., Kaplan, D. R., Cantley, L. C., Toker, A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 1997, 275: 665-8.
134. Klarlund, J. K., Guilherme, A., Holik, J. J., Virbasius, J. V., Chawla, A., Czech, M. P. Signaling by phosphoinositide-3,4,5-trisphosphate through proteins containing pleckstrin and Sec7 homology domains. Science 1997, 275: 1927-30.
135. Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron P., Morrice, N., Cohen, P., Hemmings, B. A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996, 15: 6541-51.
136. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B., Cohen, P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 1997, 7: 261-9.
137. Alessi, D. R., Deak, M., Casamayor, A., Caudwell, F. B., Morrice, N., Norman, D. G., Gaffney, P., Reese, C. B., MacDougall, C. N., Harbison, D., Ashworth, A., Bownes, M. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr. Biol. 1997, 7: 776-89.
138. Stephens, L., Anderson, K., Stokoe, D., Erdjument-Bromage, H., Painter, G. F., Holmes, A. B., Gaffney, P. R., Reese, C. B., McCormick, F., Tempst, P., Coadwell, J., Hawkins, P. T. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 1998, 279: 710-4.
139. Woodgett, J. R. Recent advances in the protein kiase B signaling pathway. Curr. Opin. Cell Biol. 2005, 17: 150-7.
140. Anderson, K. E., Coadwell, J., Stephens, L. R., Hawkins, P. T. Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B. Curr. Biol. 1998, 8: 684-91.
141. Sarbassov, D. D., Guertin, D. A., Ali, S. M., Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307: 1098-101.
142. Hresko, R. C., Mueckler, M. mTOR.RICTOR is the Ser473 kinase for Akt/ protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 2005, 280: 40406-16.
143. Vanhaesebroeck, B., Alessi, D. R. The P13K-PDK1 connection: more than just a road to PKB. Biochem. J. 2000, 346 Pt 3: 561-76.
144. Parker, P. J., Parkinson, S. J. AGC protein kinase phosphorylation and protein kinase C. Biochem. Soc. Trans. 2001, 29: 860-3.
145. Le Good, J. A., Ziegler, W. H., Parekh, D. B., Alessi, D. R., Cohen, P., Parker, P. J. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 1998, 281: 2042-5.
146. Chou, M. M., Hou, W., Johnson, J., Graham, L. K., Lee, M. H., Chen, C. S., Newton, A. C., Schaffhausen, B. S., Toker, A. Regulation of protein kinase C zeta by PI 3-kinase and PDK-1. Curr. Biol. 1998, 8: 1069-77.
147. Park, J., Leong, M. L., Buse, P., Maiyar, A. C., Firestone, G. L., Hemmings, B. A. Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. EMBO J. 1999, 18: 3024-33.
148. Lang, F., Cohen, P. Regulation and physiological roles of serum-and glucocorticoid-induced protein kinase isoforms. Sci. STKE 2001, 2001: RE17.
149. Pullen, N., Dennis, P. B., Andjelkovic, M., Dufner, A., Kozma, S. C., Hemmings, B. A., Thomas, G. Phosphorylation and activation of p70s6k by PDK1. Science 1998, 279: 707-10.
150. Alessi, D. R., Kozlowski, M. T., Weng, Q. P., Morrice, N., Avruch, J. 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr. Biol. 1998, 8: 69-81.
151. Logan, S. K., Falasca, M., Hu, P., Schlessinger, J. Phosphatidylinositol 3-kinase mediates epidermal growth factor-induced activation of the c-Jun N-terminal kinase signaling pathway. Mol. Cell Biol. 1997, 17: 5784-90.
152. Salim, K., Bottomley, M. J., Querfurth, E., Zvelebil, M. J., Gout; I., Scaife, R., Margolis, R. L., Gigg, R., Smith, C. I., Driscoll, P. C., Waterfield, M. D., Panayotou, G. Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton's tyrosine kinase. EMBO J. 1996, 15: 6241-50.
153. Li, Z., Wahl, M. I., Eguinoa, A., Stephens, L. R., Hawkins, P. T., Witte, O. N. Phosphatidylinositol 3-kinase-gamma activates Bruton's tyrosine kinase in concert with Src family kinases. Proc. Natl. Acad. Sci. USA 1997, 94: 13820-5.
154. Qiu, Y., Robinson, D., Pretlow, T. G., Kung, H. J. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinasc and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95: 3644-9.
155. Scharenberg, A. M., El-Hillal, O., Fruman, D. A., Beitz, L. O., Li, Z., Lin, S., Gout, I., Cantley, L. C., Rawlings, D. J., Kinet, J. P. Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium, signaling pathway: a target for SHIP-mediated inhibitory signals. EMBO J. 1998, 17: 1961-72.
156. Falasca, M., Logan, S. K., Lehto, V. P., Baccante, G., Lemmon, M. A., Schlessinger, J. Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting. EMBO J. 1998, 17: 414-22.
157. Gratacap, M. P., Payrastre, B., Viala, C., Mauco, G., Plantavid, M., Chap, H. Phosphatidylinositol 3,4,5-trisphosphate-dependent stimulation of phospholipase C-gamma2 is an early key event in FcgammaRIIA-mediated activation of human platelets. J. Biol. Chem. 1998, 273: 24314-21.
158. Delcommenne, M., Tan, C., Gray, V., Rue, L., Woodgett, J., Dedhar, S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc. Natl. Acad. Sci. USA 1998, 95: 11211-6.
159. Troussard, A. A., Mawji, N. M., Ong, C., Mui, A., St -Arnaud, R., Dedhar, S. Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J. Biol. Chem. 2003, 278: 22374-8.
160. Sun, H., King, A J., Diaz, H. B., Marshall, M. S. Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidylinositol 3-kinase, Cdc42/Rac and Pak. Curr. Biol. 2000, 10: 281-4.
161. Chaudhary, A., King, W. G., Mattaliano, M. D., Frost, J. A., Diaz, B., Morrison, D. K., Cobb, M. H., Marshall, M. S., Brugge, J. S. Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338. Curr. Biol. 2000, 10: 551-4.
162. Isakoff, S. J., Cardozo, T., Andreev, J., Li, Z., Ferguson, K. M., Abagyan, R., Lemmon, M. A., Aronheim, A., Skolnik, E. Y. Identification and analysis of PH domain-containing targets of phosphatidylinositol 3-kinase using a novel in vivo assay in yeast. EMBO J. 1998, 17: 5374-87.
163. Lockyer, P. J., Wennstrom, S., Kupzig, S., Venkateswarlu, K., Downward, J., Cullen, P. J. Identification of the ras GTPase-activating protein GAP1(m) as a phosphatidylinositol-3,4,5-trisphosphate-binding protein in vivo. Curr. Biol. 1999, 9: 265-8.
164. Anderson, K. E., Lipp, P., Bootman, M., Ridley, S. H., Coadwell, J., Ronnstrand, L., Lennartsson, J., Holmes, A. B., Painter, G. F., Thuring, J., Lim, Z., Erdjument-Bromage, H., Grewal, A., Tempst, P., Stephens, L. R., Hawkins, P. T. DAPP1 undergoes a PI 3-kinase-dependent cycle of plasma-membrane recruitment and endocytosis upon cell stimulation. Curr. Biol. 2000, 10: 1403-12.
165. Yang, W. C., Ching, K. A., Tsoukas, C. D., Berg, L. J. Tec kinase signaling in T cells is regulated by phosphatidylinositol 3-kinase and the Tec pleckstrin homology domain. J. Immunol. 2001, 166: 387-95.
166. Krugmann, S., Anderson, K. E., Ridley, S. H., Risso, N., McGregor, A., Coadwell, J., Davidson, K., Eguinoa, A., Ellson, C. D., Lipp, P., Manifava, M., Ktistakis, N., Painter, G., Thuring, J. W., Cooper, M. A., Lim, Z. Y., Holmes, A. B., Dove, S. K., Michell, R. H., Grewal, A., Nazarian, A., Erdjument-Bromage, H., Tempst, P., Stephens, L. R., Hawkins, P. T. Identification of ARAP3, a novel PI3K effector regulating both Arf and Rho GTPases, by selective capture on phosphoinositide affinity matrices. Mol. Cell 2002, 9: 95-108.
167. Welch, H. C., Coadwell, W. J., Ellson, C. D., Ferguson, G. J., Andrews, S. R., Erdjument-Bromage, H., Tempst, P., Hawkins, P. T., Stephens, L. R. P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell 2002, 108: 809-21.
168. Yao, R., Cooper, G. M. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 1995, 267: 2003-6.
169. Yao, R., Cooper, G. M. Growth factor-dependent survival of rodent fibroblasts requires phosphatidyhnositol 3-kinase but is independent of pp70S6K activity. Oncogene 1996, 13: 343-51.
170. Parrizas, M., Saltiel, A. R., LeRoith, D. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J. Biol. Chem. 1997, 272: 154-61.
171. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91: 231-41.
172. Marte, B. M., Downward, J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem. Sci. 1997, 22: 355-8.
173. Datta, S. R., Brunet, A., Greenberg, M. E. Cellular survival: a play in three Akts. Genes Dev. 1999, 13: 2905-27.
174. Kandel, E. S., Hay, N. The regulation and activities of the multi-functional serine/threonine kinase Akt/PKB. Exp. Cell Res. 1999, 253: 210-29.
175. Franke, T. F., Hornik, C. P., Segev, L., Shostak, G. A., Sugimoto, C. PI3K/Akt and apoptosis: size matters. Oncogene 2003, 22: 8983-98.
176. Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J., Evan, G. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997, 385: 544-8.
177. Kulik, G., Klippel, A., Weber, M. J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell Biol. 1997, 17: 1595-606.
178. Songyang, Z., Baltimore, D., Cantley, L. C., Kaplan, D. R., Franke, T. F. Interleukin 3-dependent survival by the Akt protein kinase. Proc. Natl. Acad. Sci. USA 1997, 94: 11345-50.
179. Philpott, K. L., McCarthy, M. J., Klippel, A., Rubin, L. L. Activated phosphatidylinositol 3-kinase and Akt kinase promote survival of superior cervical neurons. J. Cell Biol. 1997, 139: 809-15.
180. Eves, E. M., Xiong, W., Bellacosa A., Kennedy, S. G., Tsichlis, P. N., Rosner, M. R., Hay, N. Akt, a target of phosphatidylinositol 3-kinase, inhibits apoptosis in a differentiating neuronal cell line. Mol. Cell Biol. 1998, 18: 2143-52.
181. Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H., Downward, J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 1997, 16: 2783-93.
182. Thompson, J. E., Thompson, C. B. Putting the rap on Akt. J. Clin. Oncol. 2004, 22: 4217-26.
183. del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278: 687-9.
184. Blume-Jensen, P., Janknecht, R., Hunter, T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr. Biol. 1998, 8: 779-82.
185. She, Q. B., Solit, D. B., Ye, Q., O'Reilly, K. E., Lobo, J., Rosen, N. The BAD protein integrates survifal signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005, 8: 287-97.
186. Rena, G., Guo, S., Cichy, S. C., Unterman, T. G., Cohen, P. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J. Biol. Chem. 1999, 274: 17179-83.
187. Biggs, W. H., 3rd, Meisenhelder, J., Hunter, T., Cavenee, W. K., Arden, K. C. Protein kinase B/Akt-mediated phosphorylation promoter nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl. Acad. Sci. USA 1999, 96: 7421-6.
188. Jackson, J. G., Kreisberg, J. I., Koterba, A. P., Yee, D., Brattain, M. G. Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells. Oncogene 2000, 19: 4574-81.
189. Burgering, B. M., Kops, G. J. Cell cycle and death control: long live Forkheads. Trends Biochem. Sci. 2002, 27: 352-60.
190. Takaishi, H., Konishi, H., Matsuzaki, H., Ono, Y., Shirai, Y., Saito, N., Kitamura, T., Ogawa, W., Kasuga, M., Kikkawa, U., Nishizuka, Y. Regulation of nuclear translocation of forkhead transcription factor AFX by protein kinase B. Proc. Natl. Acad. Sci. USA 1999, 96: 11836-41.
191. van Weeren, P. C., de Bruyn, K. M., de Vries-Smits, A. M., van Lint, J., Burgering, B. M. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J. Biol. Chem. 1998, 273: 13150-6.
192. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378: 785-9.
193. Viglietto, G., Motti, M. L., Bruni, P., Melillo, R. M., D'Alessio, A., Califano, D., Vinci, F., Chiappetta, G., Tsichlis, P., Bellacosa, A., Fusco, A., Santoro, M. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med. 2002, 8: 1136-44.
194. Liang, J., Zubovitz, J., Petrocelli, T., Kotchetkov, R., Connor, M. K., Han, K., Lee, J. H., Ciarallo, S., Catzavelos, C., Beniston, R., Franssen, E., Slingerland, J. M. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated, G4 arrest. Nat. Med. 2002, 8: 1153-60.
195. Mayo, L. D., Donner, D. B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA 2001, 98: 11598-603.
196. Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., Zeiher, A. M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399: 601-5.
197. Michell, B. J., Griffiths, J. E., Mitchelhill, K. I., Rodriguez-Crespo, I., Tiganis, T., Bozinovski, S., de Montellano, P. R., Kemp, B. E., Pearson, R. B. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr. Biol. 1999, 9: 845-8.
198. Kitamura, T., Kitamura, Y., Kuroda, S., Hino, Y., Ando, M., Kotani, K., Konishi, H., Matsuzaki, H., Kikkawa, U., Ogawa, W., Kasuga, M. Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol. Cell Biol. 1999, 19: 6286-96.
199. Zimmermann, S., Moelling, K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999, 286: 1741-4.
200. Rommel, C., Clarke, B. A., Zimmermann, S., Nunez, L., Rossman, R., Reid, K., Moelling, K., Yancopoulos, G. D., Glass, D. J. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 1999, 286: 1738-41.
201. Kim, A. H., Khursigara, G., Sun, X., Franke, T. F., Chao, M. V. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol. Cell Biol. 2001, 21: 893-901.
202. Lin, H. K., Yeh, S., Kang, H. Y., Chang, C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc. Natl. Acad. Sci. USA 2001, 98: 7200-5.
203. Du, K., Montminy, M. CREB is a regulatory target for the protein kinase Akt/PKB. J. Biol. Chem. 1998, 273: 32377-9.
204. Huang, W. C., Chen, C. C. Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol. Cell Biol. 2005, 25: 6592-602.
205. Brennan, P., Babbage, J. W., Burgering, B. M., Groner, B., Reif, K., Cantrell, D. A. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity 1997, 7: 679-89.
206. Reichert, M., Saur, D., Hamacher, R., Schmid, R. M., Schneider, G. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res. 2007, 67: 4149-56.
207. Kane, L. P., Shapiro, V. S., Stokoe, D., Weiss, A. Induction of NF-kappaB by the Akt/PKB kinase. Curr. Biol. 1999, 9: 601-4.
208. Romashkova, J. A., Makarov, S. S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401: 86-90.
209. Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., Donner, D. B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401: 82-5.
210. Madrid, L. V., Wang, C. Y., Guttridge, D. C., Schottelius, A. J., Baldwin, A. S., Jr., Mayo, M. W. Akt suppresses apoptosis by stimulating the transactivation potential of the Re1A/p65 subunit of NF-kappaB. Mol. Cell Biol. 2000, 20: 1626-38.
211. Carter, B. Z., Milella, M., Altieri, D. C., Andreeff, M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood 2001, 97: 2784-90.
212. Tran, J., Master, Z., Yu, J. L., Rak, J., Dumont, D. J., Kerbel, R. S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl. Acad. Sci. USA 2002, 99: 4349-54.
213. Kuo, M. L., Chuang, S. E., Lin, M. T., Yang, S. Y. The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6. Oncogene 2001, 20: 677-85.
214. Bertram, J., Peacock, J. W., Tan, C., Mui, A. L., Chung, S. W., Gleave, M. E., Dedhar, S., Cox, M. E., Ong, C. J. Inhibition of the phosphatidylinositol 3′-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells. Cancer Res. 2006, 66: 4781-8.
215. Shamji, A. F., Nghiem, P., Schreiber, S. L. Integration of growth factor and nutrient signaling: implications for cancer biology. Mol. Cell 2003, 12: 271-80.
216. Gingras, A. C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N., Hay, N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 1998, 12: 502-13.
217. Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., Sabatini, D. M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA 1998, 95: 1432-7.
218. Hara, K., Yonezawa, K., Weng, Q. P., Kozlowski, M. T., Belham, C., Avruch, J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem. 1998, 273: 14484-94.
219. Fingar, D. C., Salama, S., Tsou, C., Harlow, E., Blenis, J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002, 16:1472-87.
220. Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., Cantley, L. C. Identification of the tuberous sclerosis complex-2 minor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 2002, 10: 151-62.
221. Gao, X., Zhang, Y., Arrazola, P., Hino, O., Kobayashi, T., Yeung, R. S., Ru, B., Pan, D. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol. 2002, 4: 699-704.
222. Inoki, K., Li, Y., Zhu, T., Wu, J., Guan, K. L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002, 4: 648-57.
223. Potter, C. J., Pedraza, L. G., Xu, T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 2002, 4: 658-65.
224. Kwiatkowski, D. J. Rhebbing up mTOR. new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biol. Ther. 2003, 2: 471-6.
225. Jacinto, E., Hall, M. N. Tor signalling in bugs, brain and brawn. Nat. Rev. Mol. Cell Biol. 2003, 4: 117-26.
226. Dan, H. C., Sun, M., Yang, L., Feldman, R. L, Sui, X. M., Ou, C. C., Nellist, M., Yeung, R. S., Halley, D. J., Nicosia, S. V., Pledger, W. J., Cheng, J. Q. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J. Biol. Chem. 2002, 277: 35364-70.
227. Garami, A., Zwartkruis, F. J., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., Kozma, S. C., Hafen, E., Bos, J. L., Thomas, G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 2003, 11: 1457-66.
228. Saucedo, L. J., Gao, X., Chiarelli, D. A., Li, L., Pan, D., Edgar, B. A. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat. Cell Biol. 2003, 5: 566-71.
229. Zhang, Y., Gao, X., Saucedo, L. J., Ru, B., Edgar, B. A., Pan, D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 2003, 5: 578-81.
230. Stocker, H., Radimerski, T., Schindelholz, B., Wittwer, F., Belawat, P., Daram, P., Breuer, S., Thomas, G., Hafen, E. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat. Cell Biol. 2003, 5: 559-65.
231. Fingar, D. C., Blenis, J. Target of rapamycin (TOR): an integmetor of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23:3151-71.
232. Plas, D. R., Thompson, C. B. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J. Biol. Chem. 2003, 278: 12361-6.
233. Matsuzaki, H., Daitoku, H., Hatta, M., Tanaka, K., Fukamizu, A. Insulin-induced phosphorylation of FKHR (Foxol) targets to proteasomal degradation. Proc. Natl. Acad. Sci. USA 2003, 100: 11285-90.
234. Aoki, M., Jiang, H., Vogt, P. K. Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc. Natl. Acad. Sci. USA 2004, 101: 13613-7.
235. Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., Gout, I., Downes, C. P., Lamb, R. F. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 2004, 166: 213-23.
236. Harrington, L. S., Findlay, G. M., Lamb, R. F. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem. Sci. 2005, 30: 35-42.
237. Martinez-Gac, L., Alvarez, B., Garcia, Z., Marques, M., Arrizabalaga, M., Carrera, A. C. Phosphoinositide 3-kinase and Forkhead, a switch for cell division. Biochem. Soc. Trans. 2004, 32: 360-1.
238. Liang, J., Slingerland, J. M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2: 339-45.
239. Alvarez, B., Martinez, A. C., Burgering, B. M., Carrera, A. C. Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 2001, 413: 744-7.
240. Hawkins, P. T., Eguinoa, A., Qiu, R. G., Stokoe, D., Cooke, F. T., Walters, R., Wennstrom, S., Claesson-Welsh, L,, Evans, T., Symons, M., et al. PDGF stimulates an increase in GTP-Rac via activation of phosphoinositide 3-kinase. Curr. Biol. 1995, 5: 393-403.
241. Hooshmand-Rad, R., Claesson-Welsh, L., Wennstrom, S., Yokote, K., Siegbahn, A., Heldin, C. H. Involvement of phosphatidylinositide 3′-kinase and Rac in platelet-derived growth factor-induced actin reorganization and chemotaxis. Exp. Cell Res. 1997, 234: 434-41.
242. Innocenti, M., Frittoli, E., Ponzanelli, I., Falck, J. R., Brachmann, S. M., Di Fiore, P. P., Scita, G. Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abil, and Sos-1. J. Cell Biol. 2003, 160: 17-23.
243. Keely, P. J., Westwick, J. K., Whitehead, I. P., Der, C. J., Parise, L. V. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 1997, 390: 632-6.
244. Shaw, L. M., Rabinovitz, I., Wang, H. H., Toker, A., Mercurio, A. M. Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell 1997, 91: 949-60.
245. Han, J., Luby-Phelps, K., Das, B., Shu, X., Xia, Y., Mosteller, R. D., Krishna, U. M., Falck, J. R., White, M. A., Broek, D. Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science 1998, 279: 558-60.
246. Sander, E. E., van Delft, S., ten Klooster, J. P., Reid, T., van der Kammen, R. A., Michiels, F., Collard, J. G. Matrix-dependent Tiam 1/Rac signaling in epithelial cells promotes either cell-cell adhesion or cell migration and is regulated by phosphatidylinositol 3-kinase. J. Cell Biol. 1998, 143: 1385-98.
247. Kim, D., Kim, S., Koh, H., Yoon, S. O., Chung, A. S., Cho, K. S., Chung, J. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J. 2001, 15: 1953-62.
248. Sliva, D., Rizzo, M. T., English, D. Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J. Biol. Chem. 2002, 277: 3150-7.
249. Zhang, G., He, B., Weber, G. F. Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer. Mol. Cell Biol. 2003, 23: 6507-19.
250. Agarwal, A., Das, K., Lerner, N., Sathe, S., Cicek, M., Casey, G., Sizemore, N. The AKT/I kappa B kinase pathway promotes angiogenic/ metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. Oncogene 2005, 24: 1021-31.
251. Belozerov, V. E., Van Meir, E. G. Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 2005, 16: 901-9.
252. Semenza, G. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 2002, 64: 993-8.
253. Bardos, J. I., Ashcroft, M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 2004, 26: 262-9.
254. Seta, K. A., Spicer, Z., Yuan, Y., Lu, G., Millhorn, D. E. Responding to hypoxia: lessons from a model cell line. Sci. STKE 2002, 2002: RE11.
255. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M. M., Simons, J. W., Semenza, G. L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60: 1541-5.
256. Gort, E. H., Groot A. J., Derks van de Ven, T. L., van der Groep, P., Verlaan, I., van Laar, T., van Diest, P. J., van der Wall, E., Shvarts, A. Hypoxia-inducible factor-1alpha expression requires PI 3-kinase activity and correlates with AktI phosphorylation in invasive breast carcinomas. Oncogene 2006, 25: 6123-7.
257. Mazure, N. M., Chen, E. Y., Laderoute, K. R., Giaccia, A. J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Haras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997, 90: 3322-31.
258. Chen, E. Y., Mazure, N. M., Cooper, J. A., Giaccia, A. J. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res. 2001, 61: 2429-33.
259. Alvarez-Tejado, M., Naranjo-Suarez, S., Jimenez, C., Carrera, A. C., Landazuri, M. O., del Peso, L. Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J. Biol. Chem. 2001, 276: 22368-74.
260. Jiang, B. H., Jiang, G., Zheng, J. Z., Lu, Z., Hunter, T., Vogt, P. K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 2001, 12: 363-9.
261. Tang, T. T., Lasky, L. A. The forkhead transcription factor FOXO4 induces the down-regulation of hypoxia-inducible factor 1 alpha by a von Hippel-Lindau protein-independent mechanism. J. Biol. Chem. 2003, 278: 30125-35.
262. Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., Abraham, R. T. Regulation of hypoxia-inducible factor lalpha expression and function by the mammalian target of rapamycin. Mol. Cell Biol. 2002, 22: 7004-14.
263. Watnick, R. S., Cheng, Y. N., Rangarajan, A., Ince, T. A., Weinberg, R. A. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003, 3: 219-31.
264. Jiang, B. H., Zheng, J. Z., Aoki, M., Vogt, P. K. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl. Acad. Sci. USA 2000, 97: 1749-53.
265. Maity, A., Pore, N., Lee, J., Solomon, D., O'Rourke, D. M. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct ftom that induced by hypoxia. Cancer Res. 2000, 60: 5879-86.
266. Blancher, C., Moore, J. W., Robertson, N., Harris, A. L. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res. 2001, 61: 7349-55.
267. Li, Y. M., Zhou, B. P., Deng, J., Pan, Y., Hay, N., Hung, M. C. A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 over-expressing cells. Cancer Res. 2005, 65: 3257-63.
268. Arsham, A. M., Plas, D. R., Thompson, C. B., Simon, M. C. Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis. Cancer Res. 2004, 64: 3500-7.
269. Hamada, K., Sasaki, T., Koni, P. A., Natsui, M., Kishimoto, H., Sasaki, J., Yajima, N., Horie, Y., Hasegawa, G., Naito, M., Miyazaki, J., Suda, T., Itoh, H., Nakao, K., Mak, T. W., Nakano, T., Suzuki, A. The PTEN/ PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev. 2005, 19: 2054-65.
270. Yorimitsu, T., Klionsky, D. J. Autophagy: molecular machinery for self-eating. Cell Death Differ. 2005, 12 Suppl 2: 1542-52.
271. Codogno, P., Meijer, A. J. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ. 2005, 12 Suppl 2: 1509-18.
272. Takeuchi, H., Kondo, Y., Fujiwara, K., Kanzawa, T., Aoki, H., Mills, G. B., Kondo, S. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol, 3-kinage/protein kinase B inhibitors. Cancer Res. 2005, 65: 3336-46.
273. Kihara, A., Noda, T., Ishihara, N., Ohsumi, Y. Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase Y sorting in Saccharomyces cerevisiae. J. Cell Biol. 2001, 152: 519-30.
274. Khalfan, W. A., Klionsky, D. J. Molecular machinery required for autophagy and the cytoplasm to vacuole targeting (Cvt) pathway in S. cerevisiae. Curr. Opin. Cell Biol. 2002, 14: 1468-75.
275. Kihara; A., Kabeya, Y., Ohsumi, Y., Yoshimori, T. Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep. 2001, 2: 130-5.
276. Wurmser, A. E., Emr, S. D. Novel PtdIns(3)P-binding protein Etf1 functions as an effectot of the Vps34 PtdIns 3-kinase in autophagy. J. Cell Biol. 2002, 158: 761-72.
277. Chang, H. W., Aoki, M., Fruman, D., Auger, K. R., Bellacosa, A., Tsichlis, P. N., Cantley, L. C., Roberts, T. M., Vogt, P. K. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 1997, 276: 1848-50.
278. Aoki, M., Batista, O., Bellacosa, A., Tsichlis, P., Vogt, P. K. The akt kinase: molecular determinants of oncogenicity. Proc. Natl. Acad. Sci. USA 1998, 95: 14950-5.
279. Aoki, M., Blazek, E., Vogt, P. K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. USA 2001, 98: 136-41.
280. Rodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A., Downward, J. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997, 89: 457-67.
281. Klippel, A., Escobedo, M. A., Wachowicz, M. S., Apell, G., Brown, T. W., Giedlin, M. A., Kavanaugh, W. M., Williams, L. T. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol. Cell Biol. 1998, 18: 5699-711.
282. Gire, V., Wynford-Thomas, D. RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation. Oncogene 2000, 19: 737-44.
283. Gire, V., Marshall, C., Wynford-Thomas, D. PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS. Oncogene 2000, 19: 2269-76.
284. Cristofanelli, B., Valentinis, B., Soddu, S., Rizzo, M. G., Marchetti, A., Bossi, G., Morena, A. R., Dews, M., Baserga, R., Sacchi, A. Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras. Oncogene 2000 19: 3245-55.
285. Sneng, H., Shao, J., DuBois, R. N. Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells. J. Biol. Chem. 2001, 276: 14498-504.
286. Janda, E., Lehmann, K., Killisch, I., Jechlinger, M., Herzig, M., Downward, J., Beug, H., Grunert, S. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J. Cell Biol. 2002, 156: 299-313.
287. Prober, D. A., Edgar, B. A. Interactions between Ras1, dMyc, and dPI3K signaling in the developing Drosophila wing. Genes Dev. 2002, 16: 2286-99.
288. Zhao, J. J., Gjoerup, O. V., Subramanian, R. R., Cheng, Y., Chen, W., Roberts, T. M., Hahn, W. C. Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 2003, 3: 483-95.
289. Blume-Jensen, P., Hunter, T. Oncogenic kinase signalling. Nature 2000, 411: 355-65.
290. Skorski, T., Bellacosa, A., Nieborowska-Skorska, M., Majewski, M., Martinez, R., Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O., Wasik, M. A., Tsichlis, P. N., Calabretta, B. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 1997, 16: 6151-61.
291. Neshat, M. S., Raitano, A. B., Wang, H. G., Reed, J. C., Sawyers, C. L. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidy-linositol 3-kinase and Raf. Mol. Cell Biol. 2000, 20: 1179-86.
292. Gesbert, F., Sellers, W. R., Signoretti, S., Loda, M., Griffin, J. D. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J. Biol. Chem. 2000, 275: 39223-30.
293. Dijkers, P. F., Medema, R. H., Pals, C., Banerji, L., Thomas, N. S., Lam, E. W., Burgering, B. M., Raaijmakers, J. A., Lammers, J. W., Koenderman, L., Coffer, P. J. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol. Cell Biol. 2000, 20 9138-48.
294. Mamillapalli, R., Gavrilova, N., Mihaylova, V. T., Tsvetkov, L. M., Wu, H., Zhang, H., Sun, H. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP 1) through the ubiquitin E3 ligase SCF(SKP2). Curr. Biol. 2001, 11: 263-7.
295. Andreu, E. J., Lledo, E., Poch, E., Ivorra, C., Albero, M. P., Martinez-Climent, J. A., Montiel-Duatte, C., Rifon, J., Perez-Calvo, J., Arbona, C., Prosper, F., Perez-Roger, I. BCR-ABL induces the expression of Skp2 through the P13K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res. 2005, 65: 3264-72.
296. Kharas, M. G., Deane, J. A., Wong, S., O'Bosky, K. R., Rosenberg, N., Witte, O. N., Fruman, D. A. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood 2004, 103: 4268-75.
297. Narita, Y., Nagane, M., Mishima, K., Huang, H. J. Furnari, F. B., Cavenee, W. K. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res. 2002, 62: 6764-9.
298. Woods Ignatoski, K. M., Livant, D. L., Markwart, S., Grewal, N. K., Ethier, S. P. The role of phosphatidylinositol 3′-kinase and its downstream signals in erbB-2-mediated transformation. Mol. Cancer Res. 2003, 1: 551-60.
299. Holbro, T., Beerli, R. R., Maurer, Y., Kihiczak, M., Barbas, C. F., 3rd, Hynes, N. E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 2003, 109: 8933-8.
300. Webster, M. A., Hutchinson, J. N., Rauh, M. J., Muthuswamy, S. K., Anton, M., Tortorice, C. G., Cardiff R. D., Graham, F. L., Hassell, J. A., Muller, W. J. Requirement for both Shc and phosphatidylinositol 3′ kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol. Cell Biol. 1998, 18: 2344-59.
301. Ichaso, N., Dilworth, S. M. Cell transformation by the middle T-antigen of polyoma virus. Oncogene 2001, 20: 7908-16.
302. Hutchinson, J., Jin, J., Cardiff, R. D., Woodgett, J. R., Muller, W. J. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol. Cell Biol. 2001, 21: 2203-12.'
303. Penuel, E., Martin, G. S. Transformation by v-Src: Ras-MAPK and PI3K-mTOR mediate parallel pathways. Mol. Biol. Cell 1999, 10: 1693-703.
304. Odajima, J., Matsumura, I., Sonoyama, J., Daino, H., Kawasaki, A., Tanaka, H., Inohara, N., Kitamura, T., Downward, J., Nakajima, K., Hirano, T., Kanakura, Y. Full oncogenic activities of v-Src are mediated by multiple signaling pathways. Ras as an essential mediator for cell survival. J. Biol. Chem. 2000, 275: 24096-105.
305. Segouffin-Cariou, C., Billaud, M. Transforming ability of MEN2ARET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J. Biol. Chem. 2000, 275: 3568-76.
306. Kamikura, D. M., Khoury, H., Maroun, C., Naujokas, M. A., Park, M. Enhanced transformation by a plasma membranc-associated met oncoprotein: ictivation of a phosphoinositide 3′-kinase-dependent autocrine loop involving hyalumnic acid and CD44. Mol. Cell Biol. 2000, 20: 3482-96.
307. Akagi, T., Shishido, T., Murata, K., Hanafusa, H. v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation. Proc. Natl. Acad. Sci. USA 2000, 97: 7290-5.
308. Stam, J. C., Geerts, W. J., Versteeg, H. H., Verkleij, A. J., van Bergen en Henegouwen, P. M. The v-Crk oncogene enhances cell survival and induces activation of protein kinase B/Akt. J. Biol. Chem. 2001, 276: 2506-83.
309. Slupianek, A., Nieborowska-Skorska, M., Hoser, G., Morrione, A., Majewski, M., Xue, L., Morris, S. W., Wasik, M. A., Skorski, T. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 2001, 61: 2194-9.
310. Chian, R., Young, S., Danilkovitch-Miagkova, A., Ronnstrand, L., Leonard, E., Ferrao,.P., Ashman, L., Linnekin, D. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood 2001, 98: 1365-73.
311. Zhao, J. J., Cheng,.H., Jia, S., Wang, L.: Gjoerup, O. V., Mikami, A., Roberts, T. M. The p110alpha isoform of P13K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl. Acad Sci. USA 2006, 103: 16296-300.
312. Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E.; Stamp, G., Alitalo, K., Dgwnward, J. Biiiding of ras to phosphoinositide 3-kinase p110alpha is required for rasdriven tumorigenesis in mice. Cell 2007, 129: 957-68.
313. Phillips, W. A., St Clair, F., Munday A. D., Thomas, R. J.. Mitchell, C. A. Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors. Cancer 1998, 83: 41-7.
314. Moore, S. M., Rintoul, R. C., Walker, T. R., Chilvers, E. R., Haslett, C. Sethi, T. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cadver cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res. 1998, 58: 5239-47.
315. Brognard, J., Clark, A. S., Ni, Y., Dennis, P. A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001, 61: 3986-97.
316. Altomare, D. A., You, H., Xiao, G. H., Ramos-Nino, M. E., Skele, K. L., De Rienzo, A., Jhanwar, S. C., Mossman, B. T., Kane, A. B., Testa, J. R. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005, 24: 6080-9.
317. Yuan, Z. Q., Sun, M., Feldman, R. I., Wang, G., Ma, X., Jiang, C., Coppola, D., Nicosia, S. V., Cheng, J. Q. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/ Akt pathway in human ovarian cancer. Oncogene 2000, 19: 2324-30.
318. Altomare, D. A., Wang, H. Q., Skele, K. L., De Rienzo, A., Klein-Szanto, A. J., Godwin, A. K., Testa, J. R. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004, 23: 5853-7.
319. Sun, M., Wang, G., Paciga, J. E., Feldman, R. I., Yuan, Z. Q., Ma, X L., Shelley, S. A., Jove, R., Tsichlis, P. N., Nicosia, S. V., Cheng, J. Q. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am. J. Pathol. 2001, 159: 431-7.
320. Ringel, M. D., Hayre, N., Saito, J., Saunier, B., Schuppert, F., Burch, H., Bernet, V., Burman, K. D., Kohn, L. D., Saji, M. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res. 2001, 61: 6105-11.
321. Gupta, A. K, McKenna, W. G., Weber, C. N., Feldman, M. D., Goldsmith, J. D., Mick, R., Machtay, M., Rosenthal, D. I., Bakanauskas, V. J., Ceriglia, G. J., Bernhard, E. J., Weber, R. S., Muschel, R. J. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin. Cancer Res. 2002, 8: 885-92.
322. Bacus, S. S., Altomare, D. A., Lyass, L., Chin, D. M., Farrell, M. P., Gurova, K., Gudkov, A., Testa, J. R. AKT-2 is ftequently upregulated. in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 2002, 21: 3532-40.
323. Itoh, N., Semba, S., Ito, M., Takeda, H., Kawata, S., Yamakawa, M. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002, 94: 3127-34.
324. Pene, F., Claessens, Y. E., Muller, O., Viguie, F., Mayeux, P., Dreyfus, F., Lacombe, C., Bouscary, D. Role of the phosphatidylinositol 3-kinase/ Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002, 21: 6587-97.
325. Xu, Q., Simpson, S. E., Scialla, T. J., Bagg, A., Carroll, M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003, 102: 972-80.
326. Min, Y. H., Eom, J. I., Cheong, J. W., Maeng, H. o., Kim, J. Y., Jeung, H. K., Lee, S. T., Lee, M. H., Hahn, J. S., Ko, Y. W. Constitutive phosphorylation of Akt/PKB; protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 2003, 17: 995-7.
327. Dhawan, P., Singh, A. B., Ellis, D. L., Richmond, A. Constitutive activation of Akt/protein kinase B in melanoma leads to upregulation of nuclear factor-kappaB and tumor progression. Cancer Res. 2002, 62: 7335-42.
328. Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P. M., Muzikansky, A., Loeffler, J. S. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J. Clin. Oncol. 2004, 22: 1926-33.
329. Amomphimoltham, P., Sriuranpong, V., Patel, V., Benavides, F., Conti, C. J., Sauk, J., Sausville, E. A., Molinolo, A. A., Gutkind, J. S. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin. Cancer Res. 2004, 10: 4029-37.
330. Cappuzzo, F., Magrini, E., Ceresoli, G. L., Bartolini, S., Rossi, E., Ludovini, V., Gregorc, V., Ligorio, C., Cancellieri, A., Damiani, S., Spreafico, A., Paties, C. T., Lombardo, L., Calandri, C., Bellezza, G., Tonato, M., Crino, L. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 2004, 96: 1133-41.
331. Cantley, L. C., Neel, B. G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/ AKT pathway. Proc. Natl. Acad. Sci. USA 1999, 96: 4240-5.
332. Leslie, N. R., Downes, C. P. PTEN: The down side of PI 3-kinase signalling. Cell Signal 2002, 14: 285-95.
333. Leevers, S. J., Vanhaesebroeck, B., Waterfield, M. D. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr. Opin. Cell Biol. 1999, 11: 219-25.
334. Sansal, I., Sellers, W. R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 2004, 22: 2954-63.
335. Maehama, T., Dixon, J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 1998, 273: 13375-8.
336. Han, S. Y., Kato, H., Kato, S., Suzuki, T., Shibata, H., Ishii, S., Shiiba, K., Matsuno, S., Kanamaru, R., Ishioka, C. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res. 2000, 60: 3147-51.
337. Myers, M. P., Pass, I., Batty, I. H., Van der Kaay, J., Stolarov, J. P., Hemmings, B. A., Wigler, M. H., Downes, C. P., Tonks, N. K. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. USA 1998, 95: 13513-8.
338. Haas-Kogan, D., Shalev, N., Wong, M., Mills, G., Yount G., Stokoe, D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol. 1998, 8: 1195-8.
339. Davies, M. A., Lu, Y., Sano, T., Fang, X., Tang, P., LaPushin, R., Koul, D., Bookstein, R., Stokoe, D., Yung, W. K., Mills, G. B., Steck, P. A. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res. 1998, 58: 5285-90.
340. Li, J., Simpson, L., Takahashi, M., Miliaresis, C., Myers, M. P., Tonks, N., Parsons, R. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res. 1998, 58: 5667-72.
341. Li, D. M., Sun, H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl. Acad. Sci. USA 1998, 95: 15406-11.
342. Gottschalk, A. R., Basila, D., Wong, M., Dean, N. M., Brandts, C. H., Stokoe, D., Haas-Kogan, D. A. p27Kip1 is required for PTEN-induced G1 growth arrest. Cancer Res. 2001, 61: 2105-11.
343. Ramaswamy, S., Nakamura, N., Vazquez, F., Batt, D. B., Perera, S., Roberts, T. M., Sellers, W. R. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA 1999, 96: 2110-5.
344. Wu, X., Senechal, K., Neshat, M. S., Whang, Y. E., Sawyers, C. L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA 1999, 95: 15587-91.
345. Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., Mak, T. W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95: 29-39.
346. Suzuki, A., de la Pompa, J. L., Stambolic, V., Elia, A. J., Sasaki, T., del Barco, Barrahtes, I., Ho, A., Wakeham, A., Itie, A. Khoo, W., Fukumoto, M., Mak, T. W. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 1998, 8: 1169-78.
347. Stambolic, V., Tsao, M. S., Macpherson, D., Suzuki, A., Chapman, W. B., Mak, T. W. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/-mice. Cancer Res. 2000, 60: 3605-11.
348. Kwabi-Addo, B., Giri, D., Schmidt, K., Podsypanina, K., Parsons, R., Greenberg, N., Ittmann, M. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad Sci.USA 2001, 98: 11563-8.
349. Backman, S. A., Ghazarian, D., So, K., Sanchez, O., Wagner, K. U., Hennighausen, L., Suzuki, A., Tsao, M. S., Chapman, W. B., Stambolic, V., Mak, T. W. Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc. Natl. Acad. Sci. USA 2004, 101: 1725-30.
350. Kimura, T., Suzuki, A., Fujita, Y., Yomogida, K., Lomeli, H., Asada, N., Ikeuchi, M., Nagy, A., Mak, T. W., Nakano, T. Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production. Development 2003, 130: 1691-700.
351. Stanger, B. Z., Stiles, B., Lauwers, G. Y., Bardeesy, N., Mendoza, M., Wang, Y., Greenwood, A., Cheng, K. H., McLaughlin, M., Brown, D., Depinho, R. A., Wu, H., Melton, D. A., Dor, Y. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 2005, 8: 185-95.
352. Sun, H., Lesche, R., Li, D. M., Liliental, J., Zhang, H., Gao, J., Gavrilova, N., Mueller, B., Liu, X., Wit, H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA 1999, 96: 6199-204.
353. Di Cristofano, A., Kotsi, P., Peng, Y. F., Cordon-Cardo, C., Elkon, K. B., Pandolfi, P. P. Impaired Fas response and autoimmunity in Pten+/ -mice. Science 1999, 285: 2122-5.
354. Weng, L. P., Smith, W. M., Dahia, P. L., Ziebold, U., Gil, E., Lees, J. A., Eng, C. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res. 1999, 59: 5808-14.
355. Lu, Y., Lin, Y. Z., LaPushin, R., Cuevas, B., Fang, X., Yu, S. X., Davies, M. A., Khan, H., Furui, T., Mao, M., Zinner, R., Hung, M. C., Steck, P., Siminovitch, K., Mills, G. B. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 1999, 18: 7034-45.
356. Paramio, J. M., Navarro, M., Segrelles, C., Gomez-Casero, E., Jorcano, J. L. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene 1999, 18: 7462-8.
357. Radu, A., Neubauer, V., Akagi, T., Hanafusa, H., Georgescu, M. M. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol. Cell Biol. 2003, 23: 6139-49.
358. Pore, N., Liu, S., Haas-Kogan, D. A., O'Rourke, D. M., Maity, A. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res. 2003, 63: 236-41.
359. Tolkacheva, T., Chan, A. M. Inhibition of H-Ras transformation by the PTEN/MMAC1/TEP1 tumor suppressor gene. Oncogene 2000, 19: 680-9.
360. Zhao, H., Dupont, J., Yakar, S., Karas, M., LeRoith, D. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 2004, 23: 786-94.
361. McMenamin, M. E., Soung, P., Perera, S., Kaplan, I., Loda, M., Sellers, W. R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999, 59: 4291-6.
362. Tsao, H., Zhang, X., Fowlkes, K., Haluska, F. G. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res. 2000, 60: 1800-4.
363. Hyun, T., Yam, A., Pece, S., Xie, X., Zhang, J., Miki, T., Gutkind, J. S., Li, W. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood 2000, 96: 3560-8.
364. Abbott, R. T., Tripp, S., Perkins, S. L., Elenitoba-Johnson, K. S., Lim, M. S. Analysis of the PI-3-Kinase-PTEN-AKT pathway in human lymphoma and leukemia using a cell line microarray. Mod. Pathol. 2003, 16: 607-12.
365. Kanamori, Y., Kigawa, J., Itamochi, H., Shimada, M., Takahashi, M., Kamazawa, S., Sato, S., Akeshima, R., Terakawa, N. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin. Cancer Res. 2001, 7: 892-5.
366. Terakawa, N., Kanamori, Y., Yoshida, S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr. Relat. Cancer 2003, 10: 203-8.
367. Ermoian, R. P., Furniss, C. S., Lamborn, K. R., Basila, D., Berger, M. S., Gottschalk, A. R., Nicholas, M. K., Stokoe, D., Haas-Kogan, D. A. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin. Cancer Res. 2002, 8: 1100-6.
368. Choe, G., Horvath, S., Cloughesy, T. F., Crosby, K., Seligson, D., Palotie, A., Inge, L., Smith, B. L., Sawyers, C. L., Mischel, P. S. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003, 63: 2742-6.
369. Podsypanina K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, I., Neshat, M., Wang, H., Yang, L., Gibbons, J., Frost, P., Dreisbach, V., Blenis, J., Gaciong, Z., Fisher, P., Sawyers, C., Hedrick-Ellenson, L., Parsons, R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice, Proc. Natl. Acad. Sci. USA 2001, 98: 10320-5.
370. Neshat, M. S., Mellinghoff, I. K., Tran,C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., Sawyers, C. L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 2001, 98: 10314-9.
371. Grunwald, V., DeGraffenried, L., Russel, D., Friedrichs, W. E., Ray, R. B., Hidalgo, M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 2002, 62: 6141-5.
372. Bianco, R., Shin, I., Ritter, C. A., Yakes, F. M., Basso, A., Rosen, N., Tsurutani, J., Dennis, P. A., Mills, G. B., Arteaga, C. L. Loss of. PTEN/ MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosifie kinase inhibitors. Oncogene 2003, 22: 2812-22.
373. She, Q. B., Solit, D., Basso, A., Moasser, M. M. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin. Cancer Res. 2003, 9: 4340-6.
374. Zhang, J., Choi, Y., Mavromatis, B., Lichtenstein, A., Li, W. Freferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Oncogene 2003, 22: 6289-95.
375. Nagata, Y., Lan, K. H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., Hortobagyi, G. N., Hung, M. C., Yu, D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6: 117-27.
376. Kau, T. R., Schroeder, F., Ramaswamy, S., Wojciechowski, C. L., Zhao, J. J., Roberts, T. M., Clardy, J., Seilers, W. R., Silver, P. A. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 2003, 4: 463-76.
377. Mayo, L. D., Donner, D. B. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem. Sci. 2002, 27: 462-7.
378. Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K., Donner, D. B. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 2002, 277: 5484-9.
379. Luo, J. M., Yoshida, H., Komura, S., Ohishi, N., Pan, L., Shigeno, K., Hanamura, I., Miura, K., Iida, S., Ueda, R., Naoe, T., Akao, Y., Ohno, R., Ohnishi, K. Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 2003, 17: 1-8.
380. Shayesteh, L., Lu, Y., Kuo, W. L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., Gray, J. W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 1999, 21: 99-102.
381. Zhang, L., Yang, N., Katsaros, D., Huang, W., Park, J. W., Fracchioli, S., Vezzani, C., Rigault de la Longrais, I. A., Yao, W., Rubin, S. C., Coukos, G. The oncogene phosphatidylinositol 3′-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Res. 2003, 63: 4225-31.
382. 4 Chang, T. C., Whang-Peng, J., Liu, J. M., Yang, D. M., Yang, W. K., Shen, C. Y. PIK3CA as an oncogene in cervical cancer. Oncogene 2000, 19: 2739-44.
383. Redon, R., Muller, D.; Caulee, K., Wanherdrick, K., Abecassis, J., du Manoir, S. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous-cell carcinomas: PIK3CA but not p63 gepe as a likely target of 3q26-qter gains. Cancer Res. 2001, 61: 4122-9.
384. Singh, B., Reddy, P. G., Goberdhan, A., Walsh, C., Dao, S., Ngai, I., Chou, T. C., P, O. C., Levine, A. J., Rao, P. H., Stoffel, A. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev. 2002, 16: 984-93.
385. Massion, P. P., Kuo, W. L., Stokoe, D., Olshen, A. B., Treseler, P. A., Chin, K., Chen, C., Polikoff, D., Jain, A. N., Pinkel, D., Albertson, D. G., Jablons, D. M., Gray, J. W. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res. 2002, 62: 3636-40.
386. Woenckhaus, J., Steger, K., Werner, E., Fenic, I., Gamerdinger, U., Dreyer, T., Stahl, U. Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J. Pathol. 2002, 198: 335-42.
387. Samuels, Y., Vang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Gazdar, A. Powell, S.M., Riggins, G.J., Willson, J.K., Markowitz, S., Kinzler, K.W., Vogelstein, B., Velculescu, V.E., High frequency of the PIk3CA gene in human cancers. Science 2004, 304: 554.
388. Samuels, Y., Velculescu, V. E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004, 3: 1221-4.
389. Parsons, D. W., Wang, T. L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K., Markowitz, S., Kinzler, K. W., Vogelstein, B., Lengauer, C., Velculescu, V. E. Colorectal cancer: mutations in a signalling pathway. Nature 2005, 436: 792.
390. Broderick, D. K., Di, C., Parrett, T. J., Samuels, Y. R., Cummins, J. M., McLendon, R. E., Fults, D. W., Velculescu, V. E., Bigner, D. D., Yan, H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 2004, 64: 5048-50.
391. Campbell, I. G., Russell, S. E., Choong, D. Y., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S., Cristiano, B. E., Pearson, R. B., Phillips, W. A. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004, 64: 7678-81.
392. Wang, Y., Helland, A., Holm, R., Kristensen, G. B., Borresen-Dale, A. L. PIK3CA mutations in advanced ovarian carcinomas. Hum. Mutat. 2005, 25: 322.
393. Levine, D. A., Bogomolniy, F., Yee, C. J., Lash, A., Barakat, R. R., Borgen, P. I., Boyd, J. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res. 2005, 11: 2875-8.
394. Lee, J. W., Soung, Y. H., Kim, S. Y., Lee, H. W., Park, W. S., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J., Lee, S. H. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24: 1477-80.
395. Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmstrom, P. O., Mansukhani, M., Enoksson, J., Hibshoosh, H., Borg, A., Parsons, R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005, 65: 2554-9.
396. Perez-Tenorio, G., Alkhori, L., Olsson, B., Waltersson, M. A., Nordenskjold, B., Rutqvist, L. E., Skoog, L., Stal, O. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin. Cancer Res. 2007, 13: 3577-84.
397. Garcia-Rostan, G., Costa, A. M., Pereira-Castro, I., Salvatore, G., Hernandez, R., Hermsem, M. J., Herrero, A., Fusco, A., Cameselle-Teijeiro, J., Santoro, M. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005, 65: 10199-207.
398. Oda, K., Stokoe, D., Taketani, Y., McCormick, F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005, 65: 10669-73.
399. Qiu, W., Schonleben, F., Li, X., Ho. D. J., Close, L. G., Manolidis, S., Bennett, B. P., Su, G. H. PIK3CA mutations in head and neck squamous cell carcinoma. Clin. Cancer Res. 2006, 12: 1441-6.
400. Schonleben, F., Qiu, W., Ciau, N. T., Ho, D. J., Li, X., Allendorf, J. D., Remotti, H. E., Su, G. H. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin. Cancer Res. 2006, 12: 3851-5.
401. Kang, S., Bader, A. G., Vogt, P. K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci USA 2005, 102: 802-7.
402. Bader, A. G., Kang, S., Vogt, P. K. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl. Acad Sci. USA 2006, 103: 1475-9.
403. Ikenoue, T., Kanai, F., Hikiba, Y., Obata, T., Tanaka, Y., Imamura, J., Ohta, M., Jazag, A., Guleng, B., Tateishi, K., Asaoka, Y., Matsumura, M., Kawabe, T., Omata, M. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 2005, 65: 4562-7.
404. Gymnopoulos, M., Elsliger, M. A., Vogt, P. K. Rare cancer-specific mutations in PIK3CA show gain of function. Proc. Natl. Acad. Sci. USA 2007, 104: 5569-74.
405. Samuels, Y., Diaz, L. A., Jr., Schmidt-Kittler, O., Cummins, J. M., Delong, L., Cheong, I., Rago, C,, Huso, D. L., Lengauer, C., Kinzler, K. W., Vogelstein, B., Velculescu, V. E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7: 561-73.
406. Guo, X. N., Rajput, A., Rose, R., Hauser, J., Beko, A., Kuropatwinski, K., LeVea, C., Hoffman, R. M., Brattain, M. G., Wang, J. Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model. Cancer Res. 2007, 67: 5851-8.
407. Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., Brugge, J. S. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005, 65: 10992-1000.
408. Zhao, J. J., Liu, Z., Wang, L., Shin, E., Loda, M. F., Roberts, T. M. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc. Natl. Acad. Sci. USA 2005, 102: 18443-8.
409. Kang, S., Denley, A., Vanhaesebroeck, B., Vogt, P. K. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinosifide 3-kinase. Proc. Natl. Acad. Sci. USA 2006, 103: 1289-94.
410. Jimenez, C., Jones, D. R., Rodriguez-Viciana, P., Gonzalez-Garcia, A., Leonardo, E., Wennstrom, S., von Kobbe, C., Toran, J. L., L, R. B., Calvo, V., Copin, S. G., Albar, J. P., Gaspar, M. L., Diez, E., Marcos, M. A., Downward, J., Martinez, A. C., Merida, I., Carrera, A. C. Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J. 1998, 17: 743-53.
411. Borlado, L. R., Redondo, C., Alvarez, B., Jimenez, C., Criado, L. M., Flores, J., Marcos, M. A., Martinez, A. C., Balomenos, D., Carrera, A. C. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J. 2000, 14: 895-903.
412. Janssen, J. W., Schleithoff, L., Bartram, C. R., Schulz, A. S. An oncogenic fusion product of the phosphatidylinositol 3-kinase p85beta subunit and HUMORF8, a putative deubiquitinating enzyme. Oncogene 1998, 16: 1767-72.
413. Philp, A. J., Campbell, I. G., Leet, C., Vincan, E., Rockman, S. P., Whitehead, R. H., Thomas, R. J., Phillips, W. A. The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001, 61: 7426-9.
414. Jucker, M., Sudel, K., Horn, S., Sickel, M., Wegner, W., Fiedler, W., Feldman, R. A. Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia 2002, 16: 894-901.
415. Schultz, R. M., Merriman, R. L., Andis, S. L., Bonjouklian, R., Grindey, G.-B., Rutherford, P. G., Gallegos, A., Massey, K., Powis, G. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res. 1995, 15: 1135-9.
416. West, K. A., Castillo, S. S., Dennis, P. A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat. 2002, 5: 234-48.
417. Skorski, T., Kanakaraj, P., Nieborowska-Skorska, M., Ratajczak, M. Z., Wen, S. C., Zon, G., Gewirtz, A. M., Perussia, B., Calabretta., B. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995, 86: 726-36.
418. Price, B. D., Youmell, M. B. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res. 1996, 56: 246-50.
419. Hosoi, Y., Miyachi, H., Matsumoto, Y., Ikehata, H., Komura, J., Ishii, K., Zhao, H. J., Yoshida, M., Takai, Y., Yamada, S., Suzuki, N., Ono, T. A phosphatidylinositol 3-kinase inhibitor wortmannin induces radioresistant DNA synthesis and sensitizes cells to bleomycin and ionizing radiation. Int. J. Cancer 1998, 78: 642-7.
420. Collis, S. J., Swartz, M. J., Nelson, W. G., De Weese, T. L. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res. 2003, 63: 1550-4.
421. Toretsky, J. A., Thakar, M., Eskenazi, A. E., Frantz, C. N. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. Cancer Res. 1999, 59: 5745-50.
422. O'Gorman, D. M., McKenna, S. L., McGahon, A. J., Knox, K. A., Cotter, T. G. Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia 2000, 14: 602-11.
423. Ng, S. S. W., Tsao, M. S., Chow, S., Hedley, D. W. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 2000, 60: 5451-5.
424. Hayakawa, J., Ohmichi, M., Kurachi, H., Kanda, Y., Hisamoto, K., Nishio, Y., Adachi, K., Tasaka, K., Kanzaki, T., Murata, Y. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res. 2000, 60: 5988-94.
425. Mabuchi, S., Ohmichi, M., Kimura, A., Hisamoto, K., Hayakawa, J., Nishio, Y., Adachi, K., Takahashi, K., Arimoto-Ishida, E., Nakatsuji, Y., Tasaka, K., Murata, Y. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J. Biol. Chem. 2002, 277: 33490-500.
426. Westfall, S. D., Skinner, M. K. Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment. Mol. Cancer Ther. 2005, 4: 1764-71.
427. Clark, A. S., West, K., Streicher, S., Dennis, P. A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 2002, 1: 707-17.
428. Liang, K., Jin, W., Knuefermann, C., Schmidt, M., Mills, G. B., Ang, K. K., Milas, L., Fan, Z. Targeting the phosphatidylinositol-3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol. Cancer Ther. 2003, 2: 353-60.
429. Knuefermann, C., Lu, Y., Liu, B., Jin, W., Liang, K., Wu, L., Schmidt, M., Mills, G. B., Mendelsohn, J., Fan, Z. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003, 22: 3205-12.
430. Bondar, V. M., Sweeney-Gotsch, B., Andreeff, M., Mills, G. B., McConkey, D. J. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol. Cancer Ther. 2002, 1: 989-97.
431. Krystal, G. W., Sulanke, G., Litz, J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol. Cancer Ther. 2002, 1: 913-22.
432. Neri, L. M., Borgatti, P., Tazzari, P. L., Bortul, R., Cappellini, A., Tabellini, G., Bellacosa, A., Capitani, S., Martelli, A. M. The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-Tetinoic acid resistance of leukemia cells. Mol. Cancer Res. 2003, 1: 234-46.
433. Bortul, R., Tazzari, P. L., Cappellini, A., Tabellini, G., Billi, A. M., Bareggi, R., Manzoli, L., Cocco, L., Martelli, A. M. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation. Leukemia 2003, 17: 379-89.
434. Reinhold, W. C., Kouros-Mehr, H., Kohn, K. W., Maunakea, A. K., Lababidi, S., Roschke, A., Stover, K., Alexander, J., Pantazis, P., Miller, L., Liu, E., Kirsch, I. R., Urasaki, Y., Pommier, Y., Weinstein, J. N. Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res. 2003, 63: 1000-11.
435. Shingu, T., Yamada, K., Hara, N., Moritake, K., Osagor, H., Terashima, M., Uemura, T., Yamasaki, T., Tsuchiya, M. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells. Cancer Res. 2003, 63: 4044-7.
436. Gupta, A. K., Bakanauskas, V. J., Cerniglia, G. J., Cheng, Y., Bernhard, E. J., Muschel, R. J., McKenna, W. G. The Ras radiation-resistance pathway. Cancer Res. 2001, 61: 4278-82.
437. Grana, T. M., Rusyn, E. V., Zhou, H., Sartor, C. I., Cox, A. D. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res. 2002, 62: 4142-50.
438. Hu, L., Hofmann, J., Lu, Y., Mills, G. B., Jaffe,, R. B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 2002, 62: 1087-92.
439. Semba, S., Itoh, N., Ito, M., Harada, M., Yamakawa, M. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol Y-kinase, in human colon cancer cells. Clin. Cancer Res. 2002, 8: 1957-63.
440. Chakravarti, A., Chakladar, A., Delaney, M. A., Latham, D. E., Loeffler, J. S. The epidermal growth factor receptor pathway mediates resistance to sequentiat administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 2002, 62: 4307-15.
441. Abdul-Ghani, R., Serra, V., Gyorffy, B., Jurchott, K., Solf, A., Dietel, M., Schafer, R. The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 2006, 25: 1743-52.
442. Su, J. D., Mayo, L. D., Donner, D. B., Durden, D. L. PTEN and phosphatidylinositol 3′-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res. 2003, 63: 3585-92.
443. Hu, L., Hofmann, J., Holash, J., Yancopoulos, G. D., Sood, A. K., Jaffe, R. B. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin. Cancer Res. 2005, 11: 6966-71.
444. Bedogni, B., O'Neill, M. S., Welford, S. M., Bouley, D. M., Giaccia, A. J., Denko, N. C., Powell, M. B. Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res. 2004, 64: 2552-60.
445. Klejman, A., Rushen, L., Morrione, A., Slupianek, A., Skorski, T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 2002, 21: 5868-76.
446. Yaguchi, S., Fukui, Y., Koshimizu, I., Yoshimi, H., Matsuno, T., Gouda, H., Hirono, S., Yamazaki, K., Yamori, T. Antitumor activityy of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J. Natl. Cancer Inst. 2006, 98: 545-56.
447. Chun, K. H., Kosmeder, J. W., 2nd, Sun, S., Pezzuto, J. M., Lotan, R., Hong, W. K., Lee, H. Y. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human, bronchial epithelial cells: J. Natl. Cancer Inst. 2003, 95: 291-302.
448. Bortul, R., Tazzari, P. L., Billi, A. M., Tabellini, G., Mantovani, I., Cappellini, A., Grafone, T., Martinelli, G., Conte, R., Martelli, A. M. Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. Br. J. Haematol.2005, 129: 677-86.
449. S tephens, L., Williams, R., Hawkins, P. Phosphoinositide 3-kinases as drug targets in cancer. Curr. Opin. Pharmacol. 2005, 5:357-65.
450. Workman, P. Inhibiting the phosphomositide 3-kinase pathway for cancer treatment. Biochem. Soc. Trans. 2004, 32: 393-6.
451. Kang, S., Bader, A. G., Zhao, L., Vogt; P. K. Mutated PI3-kinases: cancer targets on a silver platter. Cell Cycle 2005, 4: 578-8.
452. Simon, J. A. Using isoform-specific inhibitors to target lipid kinases. Cell 2006, 125: 647-9.
453. Sadhu, C., Masinovsky, B., Dick, K., Sowell, C. G., Staunton, D. E. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J. Immunol. 2003, 170: 2647-54.
454. Sadhu, C., Dick, K., Tino, W. T., Staunton, D. E. Selective role of PI3K delta in neutrophil inflammatory responses. Biochem. Biophys. Res. Commun. 2003, 308: 764-9.
455. Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt; W. S., Yap, C. L., Wright, C. E., Kenche, V., Anderson, K. E., Dopheide, S. M., Yuan, Y., Sturgeon, S. A., Prabaharan, H., Thompson, P. E., Smith, G. D., Shepherd, P. R., Daniele, N., Kulkarni, S., Abbott, B., SayU, D., Jones, C., Lu, L., Giuliano, S., Hughan, S. C., Angus, J. A., Robertson, A. D., Salem, H. H. PI3-kinase p110beta: a new target for antithrombotic therapy. Nat. Med. 2005, 11: 501-14.
456. Condliffe, A. M., Davidson, K., Anderson, K. E., Ellson, C. D., Crabbe, T., Okkenhaug, K., Vanhaesebroeck, B., Turner, M., Webb, L., Wymann, M. P., Hirsch, E., Ruckle, T., Camps, M., Rommel, C., Jackson, S. P., Chilvers, E. R., Stephens, L. R., Hawkins, P. T. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 2005, 106: 1432-40.
457. Camps, M., Ruckle, T., Ji, H., Ardissone, V., Rintelen, F., Shaw, J., Ferrandi, C., Chabert, C., Gillieron, C., Francon, B., Martin, T., Gretener, D., Perrin, D., Leroy, D., Vitte, P. A., Hirsch, E., Wyman, M. P., Cirillo, R., Schwarz, M. K., Rommel, C. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 2005, 11: 936-43.
458. Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., Balls, T., Weiss, W. A., Williams, R. L., Shokat, K. M. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006, 125: 733-47.
459. Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A. J., Withers, D. J., Vanhaesebroeck, B. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 2006, 441: 366-70.
460. Sawyer, C., Sturge, J., Bennett, D. C., O'Hare, M. J., Allen, W. E., Bain, J., Jones, G. E., Vanhaesebroeck, B. Regulation of breast cancer cell chernotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res. 2003, 63: 1667-75.
461. Geng, L., Tan, J., Himmelfarb, E., Schueneman, A., Niermann, K., Brousal, J., Fu, A., Cuneo, K., Kesicki, E. A., Treiberg, J., Hayflick, J. S., Hallahan, D. E. A specific antagonist of the p110delta catalytic component of phosphatidylinositol 3′-kinase, IC486068, enhances radiation-induced tumor vascular destruction. Cancer Res. 2004, 64: 4893-9.
462. Sujobert, P., Bardet, V., Cornillet-Lefebvre, P., Hayflick, J. S., Prie, N., Verdier, F., Vanhaesebroeck, B., Muller, O., Pesce, F., Ifrah, N., Hunault-Berger, M., Berthou, C., Villemagne, B., Jourdan, E., Audhuy, B., Solary, E., Witz, B., Harousseau, J. L., Himberlin, C., Lamy, T., Lioure, B., Cahn, J. Y., Dreyfus, F., Mayeux, P., Lacombe, C., Bouscary, D. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005, 106: 1063-6.
463. Billottet, C., Grandage, V. L., Gale, R. E., Quattropani, A., Rommel, C., Vanhaesebroeck, B., Khwaja, A. A selective inhibitor of the p110delta isoform of PI3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 2006.
464. Ihle, N. T., Williams, R., Chow, S., Chew, W., Berggren, M. I., Paine-Murrieta, G., Minion, D. J., Halter, R. J., Wipf, P., Abraham, R., Kirkpatrick, L., Powis, G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther. 2004, 3: 763-72.
465. Ihle, N. T., Paine-Murrieta, G., Berggren, M. I., Baker, A., Tate, W. R., Wipf, P., Abraham, R. T., Kirkpatrick, D. L., Powis, G. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol. Cancer Men 2005, 4: 1349-57.
466. Fan, Q. W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., Weiss, W. A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006, 9. 341-9.
467. Yang, L., Dan, H. C., Sun, M., Liu, Q., Sun, X. M., Feldman, R. I., Hamilton, A. D., Polokoff, M., Nicosia, S. V., Herlyn, M., Sebti, S. M., Cheng, J. Q. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 2004, 64: 4394-9.
468. DeFeo-Jones, D., Barnett, S. F., Fu, S., Hancock, P. J., Haskell, K. M., Leander, K. R., McAvoy, E., Robinson, R. G., Duggan, M. E., Lindsley, C. W., Zhao, Z., Huber, H. E., Jones, R. E. Tumor cell sensitization to apoplotic stimull by selective inhibition of-specific Akt/PKB family members. Mol. Cancer Ther. 2005, 4: 271-9.
469. Li, Z., Jaboin, J., Dennis, P. A., Thiele, C. J. Genetic and pharmacologic identification of Akt as a mediator of braill-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death. Cancer Res. 2005, 65: 2070-5.
470. Mandal, M., Kim, S., Younes, M. N., Jasser, S. A., El-Naggar, A. K., Mills, G. B., Myers, J. N. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br. J. Cancer, 2005, 92: 1899-905.
471. Koul, D., Shen, R., Bergh, S., Shong, X., Shishodia, S., Lafortune, T. A,, Lu, Y., de Groot, J. F., Mills, G. B., Yung, W. K. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol. Cancer Ther. 2006, 5: 637-44.
472. Rowinsky, E. K. Targeting the molectilar target of Tapamycin (mTOR). Curr. Opin. Oncol. 2004, 16: 564-75.
473. Hay, N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005, 8: 179-83.
474. Faivre, S., Kroemer, G., Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 2006, 5: 671-88.
475. Easton, J. B., Kurmasheva, R. T., Houghton, P. J. IRS-1: auditing the effectiveness of mTOR inhibitors. Cancer Cell 2006, 9: 153-5.
476. Sun, S. Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., Khuri, F. R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of mpamycin inhibition. Cancer Res. 2005, 65: 7052-8.
477. O'Reilly, K. E., Rojo, F., She, Q. B., Solit, D., Mills, G. B., Smith, D., Lane, H,, Hofmann, F., Hicklin, D. J., Ludwig, D. L., Baselga, J., Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66: 1500-8.
478. Wan, X., Harkavy, B., Shen, N., Grohar, P., Helman, U. J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26: 1932-40.
479. Li, I, Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H., Parsons, R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275: 1943-7.
480. Risinger, J. I., Hayes, A. K., Berchuck, A., Barrett, J. C. FTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997, 57: 4736-8.
481. Tashiro, H., Blazes, M. S., Wu, R., Cho, K. R., Bose, S., Wang, I., Li, J., Parsons, R., Ellenson, L. H. Mutations in PTEN: are frequent in endometrial carcinoma but rait in other common gynecological malignancies. Cancer Res. 1997, 57: 3935-40.
482. Liaw, D., Marsh, D. J., Li, J., Dahia, P. L., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacocke, M., Eng, C., Parsons, R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 1997, 16: 64-7.
483. Eng, C. Will the real Cowden syndrome please stand up:revised diagnostic criteria. J. Med. Genet. 2000, 37: 828-30.
484. Mirmohammadsadeih,, A. Marini, A., Nambiar,, S., Hassan, M., Tannapfel, A., Ruzicka, T., Hengge, U. R., Epigenetic silencing of the PTEN gone in melanenoma. Cancer Res. 2006, 66: 6546-52.
485. Goel, A:., Arnold, C. N., Niedzwiecki, D., Carethers, J. M., Dowell, J. M., Wasserman, L., Compton, C., Mayer, R. J., Bertagnolli, M. M., Boland, C. R. Frequent inactivetiw of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 2004, 64: 3014-21.
486. Garcia, J. M., Silva, J., Pena, C,, Garcia, V., Rodriguez, R., Cruz, M. A., Cantos, B., Provencio, M., Espana, P., Bonilla, F., Promoter methylation of the PTRN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 2004, 41: 117-24.
487. Eng, C. PTEN: one gene, many syndromes. Hum. Mutat. 2003, 22: 183-98.
488. Byun, D. S., Cho, K., Ryu, B. K., Lee, M. G., Park, J. I., Chae, K. S., Kim, H. J., Chi, S. G. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int J. Cancer 2003, 104: 318-27.
489. Racz, A., Brass, N., Heckel, D., Pahl, S., Remberger, K., Meese, E. Expression analysis of genes at 3q26-q27 involved in frequent amplification in squamous cell lung carcinoma. Eur. J. Cancer 1999, 35: 641-6.
490. Mizoguchi, M., Nutt, C. L., Mohapatra, G., Louis, D. N. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol. 2004, 14: 372-7.
491. Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., Uhlik, M., Lin, A., Du, J., Qian, Y. W., Zeckner, D. J., Tucker-Kellogg, G., Touchman, J., Patel, K., Mousses, S., Bittner, M., Schevitz, R., Lai, M. H., Blanchard, K. L., Thomas, J. E. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007.
492. Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., Testa, J. R. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified. in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA 1992, 89: 9267-71.
493. Bellacosa, A., de Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q. Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., Ferrandina, G., Benedetti Panici, P., Mancuso, S., Neri, G., Testa, J. R. Molecular alterations of the AKT2 oncogener in ovarian and breast carcinomas. Int. J. Cancer 1999, 64: 280-5.
494. Arranz, E., Robledo, M., Martinez, B., Gallego, J., Roman, A., Rivas, C., Benitez, J. Incidence of homogeneously staining regions in non-Hodgkin lymphomas. Cancer Genet. Cytogenet. 1996, 87: 1-3.
495. Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., Testa, J. R. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expres?ion and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. USA 1996, 93: 3636-41.
496. Hornigold, N., Devlin, J., Davies, A. M., Aveyard, J. S., Habuchi, T., Knowles, M. A. Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 1999, 18: 2657-61.